EP2635140A1 - Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections - Google Patents

Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections

Info

Publication number
EP2635140A1
EP2635140A1 EP11797362.8A EP11797362A EP2635140A1 EP 2635140 A1 EP2635140 A1 EP 2635140A1 EP 11797362 A EP11797362 A EP 11797362A EP 2635140 A1 EP2635140 A1 EP 2635140A1
Authority
EP
European Patent Office
Prior art keywords
skin
complexion
fatty acid
use according
imperfections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP11797362.8A
Other languages
German (de)
French (fr)
Inventor
Audrey Gueniche
Isabelle Castiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
LOreal SA
Original Assignee
Nestec SA
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA, LOreal SA filed Critical Nestec SA
Publication of EP2635140A1 publication Critical patent/EP2635140A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/48—Moist feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Definitions

  • the present invention relates to the field of cosmetic and / or dermatological products and dietary supplements intended for the care of the complexion of the skin.
  • the present invention proposes the use of a new active agent for treating and / or preventing aesthetic skin defects of the complexion of the skin.
  • the present invention also relates to methods suitable for the treatment and / or prevention of imperfections and inhomogeneities of the complexion of the skin.
  • Extrinsic factors that may affect skin tone include exposure to the sun, exposure to temperature and / or humidity changes, exposure to pollutants or cigarette smoke.
  • Intrinsic factors that affect skin tone include stress, fatigue, hormonal changes, dehydration of the skin, impaired skin barrier function, aging, or excessive secretion of sebum.
  • genetic factors can affect the sensitivity of individuals to external conditions that may affect the skin's complexion.
  • the object of the present invention is to satisfy these needs.
  • the present invention relates to an oral or nutraceutical cosmetic use of an effective amount of at least one monounsaturated fatty acid, a salt thereof and / or an ester thereof. , as an active ingredient to treat and / or prevent imperfections of the complexion of the skin.
  • Monounsaturated fatty acids have been described for various applications, such as the hydration of dry skin in EP 0 709 084 or the treatment of dandruff and itching of the scalp in EP 0 116 439.
  • WO 01/08651 discloses a composition comprising petroselinic acid for controlling the secretion of sebum and lightening the complexion of the skin.
  • EP 0 355 842 discloses a care cream intended to prevent pigmentation caused by an overproduction of melanin, said cream possibly containing petroselinic acid.
  • EP 1 013 178 discloses the use of petroselinic acid as an anti-inflammatory agent and for treating the skin signs of aging, such as wrinkles, flabby skin, and senescence patches.
  • WO 99/47110 discloses a cosmetic method for improving the appearance of skin using petroselinic acid.
  • No. 6,022,890 describes a composition comprising an alpha hydroxy acid, petroselinic acid and a cosmetically acceptable vehicle.
  • the inventors have been able to demonstrate that monounsaturated fatty acids, in particular petroselinic acid, lead to the restoration of normal skin tissue in perfect homeostasis with a radiant, young and healthy complexion.
  • an individual treated according to the invention can advantageously see the imperfections of the complexion of his skin reduce or even disappear.
  • the complexion of the skin can become homogeneous, without dyschromism, without dull aspect, and devoid of impurity.
  • the invention makes it possible to give the complexion of the skin, in particular of the skin of the face, a radiant and radiant appearance.
  • skin is intended to denote the entire skin of an individual, in particular a human being, and more particularly the skin of the face, neck and Vietnameselleté.
  • skin includes surfaces covered with hair.
  • the invention is more particularly suitable for the care of the skin of the face, neck and Vietnameselleté, and preferably for the care of the skin of the face.
  • the present invention relates to an oral cosmetic treatment method, useful for treating and / or preventing imperfections of skin tone in an individual in need, comprising at least one step of administering to said individual an effective amount of at least one monounsaturated fatty acid, a salt thereof and / or an ester thereof.
  • the present invention advantageously makes it possible to prevent and / or treat imperfections of the complexion of the skin.
  • the invention advantageously makes it possible to prevent and / or treat a dull, dull and / or inhomogeneous skin complexion.
  • the invention advantageously makes it possible to prevent and / or treat imperfections in the complexion of the skin, chosen from pimples, scabs, dyschromias or blackheads.
  • a use according to the invention advantageously makes it possible to prevent and / or treat a waxy, yellowish or even sickly complexion.
  • An implementation of a monounsaturated fatty acid according to the invention is necessarily in an effective amount, ie an amount allowing the fatty acid to show its active properties with regard to imperfections of the complexion of the skin to prevent and / or treat.
  • the term "prevent” means reducing to a lesser degree the risk or the probability of manifestation of a given phenomenon, i.e. in the present invention an imperfection of the complexion of the skin.
  • the term "monounsaturated fatty acid” in the sense of the present invention a fatty acid whose hydrocarbon chain comprises a single double bond.
  • the monounsaturated fatty acids that are suitable for the invention are, in particular, monounsaturated fatty acids containing a hydrocarbon chain containing from 12 to 22 carbon atoms.
  • the monounsaturated fatty acids that are suitable for the invention can be used in acid form, or in the form of a salt, or else in the form of derivatives, in particular fatty acid esters and amides.
  • the monounsaturated fatty acids of the invention are more particularly cosmetically acceptable salts, that is to say, inorganic salts, such as ammonium or metal salts.
  • inorganic salts such as ammonium or metal salts.
  • alkaline such as lithium, potassium, sodium, alkaline earth salts, such as magnesium, or calcium, or aluminum salts.
  • the monounsaturated fatty acids that are suitable for the invention may be in the form of calcium salts.
  • the monounsaturated fatty acids of the invention can be esterified with glycerol in the form of mono-, di- or tri-acyl, with an alcohol such as methyl and ethyl alcohols, with a sugar, in particular a mono or a disaccharide, a tocopherol, a tocotrienol, a sterol, such as cholesterol or a phytosterol, such as ⁇ -sitosterol, or with a fatty alcohol, especially in Cs It is understood that the choice of monounsaturated fatty acids of the invention is carried out taking into account the purpose of the composition comprising them.
  • the administration of a monounsaturated fatty acid according to the invention is carried out orally.
  • the mono-unsaturated fatty acid of the invention, its and / or its ester can be used in an oral composition in which the content of said monounsaturated fatty acid, its salt and / or its ester is such that the daily dose varies from 0.5 to 2500 mg / day, and in particular from 5 to 500 mg / day.
  • oleic acid or petroselinic acid is particularly used.
  • petroselinic acid is particularly suitable for the invention.
  • the monounsaturated fatty acid or acids are used in an isolated form, that is to say after extraction of their original source.
  • the monounsaturated fatty acids or acids are used in a plant extract such as an oil.
  • the invention relates in particular to the cosmetic use of a monounsaturated fatty acid-rich oil of the invention, and in particular rich in petroselinic acid.
  • the oils rich in petroselinic acid are more particularly chosen from umbelliferous oils.
  • Oil rich in petroselinic acid is understood to mean an oil comprising at least 40% of pretroselinic acid.
  • Umbelliferae are plants whose flowers are arranged in umbels, species particularly rich in petroselenic acid are Umbellifarea-Apiacea and Araliaceae. Plants of the genus Thapsia are also sources of petroselenic acid (Avato et al, Lipids, 2001, 36, 845).
  • the preferred species used in the invention are coriander, chervil, carrot, celery, caraway, caraway, parsley and dill.
  • the umbelliferous oil used according to the invention can be extracted from the seed of an umbellifer, for example by grinding or pressing, then refining.
  • Umbellifer oil has a petroselinic acid content that varies according to the umbelliferous seed from which it is extracted.
  • the petroselinic acid content also varies according to the country of origin of the Ombellifer and according to the extraction which can be more or less complete.
  • Petroselenic acid is also an abundant (about 48%) compound of Gernium sanguneum seed oil (Tsevegsuren et al., Lipids, 2004, 39, 571).
  • the monounsaturated fatty acid more particularly considered in the invention is petroselenic acid.
  • petroselenic acid can be used in the form of umbelliferous oil or Gernium sanguneum.
  • the umbelliferous oil more particularly considered in the invention can be chosen from coriander, chervil, carrot, celery, caraway, caraway, parsley, d dill, and mixtures thereof.
  • the invention makes it possible to improve, homogenize or restore the complexion of the skin.
  • the invention aims to prevent and / or treat imperfections of the complexion of the skin.
  • the term "imperfections of the complexion of the skin” means an alteration of the natural appearance of a healthy skin.
  • the imperfections of the complexion of the skin considered in the invention do not include the alterations of the skin resulting from inflammatory phenomena such as inflammatory redness.
  • the imperfections of the complexion of the skin considered in the invention do not include skin defects related to overproduction of melanin.
  • the imperfections of skin tone considered in the invention do not include skin surface defects, such as roughness or crevices.
  • the imperfections of the complexion of the skin within the meaning of the invention do not include the defects of clarity of the complexion and the implementation of the invention is not intended to lighten the complexion of the skin or to whiten the skin.
  • imperfections of the complexion of the skin considered by the invention may, in particular, be chosen from scrambled skins, dull skins, hides with an inhomogeneous complexion, or skins presenting impurities or dyschromias.
  • the term "impurities of the skin”, cysts, comedones, cicatricial lesions with or without dyschromia is intended to mean that the excretion of the skin.
  • revealing the radiance of the complexion of the skin can in no way be equated with an action to lighten the skin's complexion.
  • the radiance of the complexion of the skin shows the natural radiance of the complexion of the skin characteristic of young and healthy skin.
  • the invention makes it possible to confer a skin tone less dull, less scrambled and less gray, and more radiant.
  • compositions according to the invention are administered orally.
  • the compositions according to the invention may be in any of the galenical forms normally used according to the route of use.
  • composition according to the invention comprises a physiologically or pharmaceutically acceptable medium.
  • the oral and / or parenteral route has the advantage of acting more generally on the entire skin and in these deep layers.
  • composition for the oral route is meant, for example, nutritional, nutraceutical or cosmeceutical compositions, comprising at least one monounsaturated fatty acid according to the invention, one of its salts and / or one of its esters.
  • composition suitable for oral administration the use of an ingestible carrier is preferred.
  • the unmanageable support may be of various nature depending on the type of composition considered.
  • oral compositions for ingestion, many embodiments of oral compositions and in particular dietary supplements are possible.
  • compositions can be carried out by any usual method known to those skilled in the art to produce, for example, oral solutions, dragees, capsules, gels, emulsions, swallowing or chewable tablets, capsules, especially soft or hard capsules, granules for dissolving, syrups, solid or liquid foods and hydrogels for controlled release.
  • tablets, capsules or lozenges for example, tablets, capsules or lozenges, suspensions, oral supplements in dry form and oral supplements in liquid form are suitable.
  • the active (s) according to the invention can be incorporated into all forms of food supplements or fortified foods, for example food bars, or compacted powders or not.
  • the powders can be diluted with water, in soda, dairy products or soy derivatives, or incorporated into food bars.
  • a composition according to the invention administered orally can be formulated in the form of dragee, capsule, gel, emulsion, tablet, capsule, hydrogel, food bar, compacted powder or not, suspension or liquid solution, confectionery, fermented milk, fermented cheese, chewing gum, toothpaste or spray solution.
  • Milk, yoghurt, cheese, fermented milks, fermented milk products, ice cream, fermented and non-fermented cereal products, milk-based powders, for example, are suitable as food carriers, formulas for children and infants, especially pet food, tablets or tablets, suspensions of liquid bacteria, oral supplements in dry form and oral supplements in liquid form.
  • the oral compositions may be in anhydrous form or in aqueous form according to the dermocosmetic indication.
  • the active agents according to the invention may be formulated with the excipients and components customary for such oral compositions or food supplements, namely in particular fatty and / or aqueous components, humectants, thickeners, preservatives, texture and flavoring agents. and / or coating, antioxidants, preservatives and dyes customary in the field of food.
  • the composition according to the invention may be a food composition for human consumption.
  • This may include, in particular, nutritional supplements, beverages, mineral waters, soups, dietary supplements and substitute or substitute foods, nutritional bars, confectionery, milk-based products or based on fermented milk, yogurts, milk-based powders, enteral nutrition products, compositions for children and / or infants, fermented or non-fermented cereal products, ice cream, chocolate, coffee "culinary" products such as mayonnaise, tomato puree or salad dressings.
  • composition according to the invention may also be intended for animals, in particular for domestic animals, such as cats and dogs, and may be formulated as food or feed supplements for animals.
  • a monounsaturated fatty acid according to the invention may advantageously be used in combination with an additional active ingredient, in particular a cosmetic or pharmaceutical ingredient.
  • such additional active ingredient, cosmetic or pharmaceutical may be intended to exert a cosmetic, care or hygiene effect on the skin, the hair, the eyelashes, the hairs and / or the scalp, and preferentially on the skin .
  • the additional active agents are chosen by those skilled in the art so that they do not interfere with the effect of the monounsaturated fatty acids of the invention.
  • an additional asset that is suitable for the invention may be chosen from active agents intended to treat and / or prevent oily or oily skin.
  • vitamins such as vitamins A, B5, B6, B8, C, D, E, or PP (vitamin B3 or niacin), antioxidants, such as curcuminoids; carotenoids, in particular a carotenoid chosen from ⁇ -carotene, lycopene and its derivatives, such as cis-lycopene or lactolycopene, astaxanthin, zeaxanthin and lutein or the compounds containing them, such as wolfberry or lactowolfberry; polyphenol compounds, flavonoids such as catechins; hesperidin, proanthocyanidins, anthocyanins, OPCs (procyanidolic oligomers); ubiquinones; coffee extracts containing polyphenols and / or diterpenes; chicory extracts; ginkgo biloba extracts; grape extracts rich in proanthocyanidins; chili extracts; soy extracts; cocoa or lactocacao; the grenade ;
  • amino acids especially sulfur-containing amino acids, such as glutathione precursors, taurine, the amino acids of selenium,
  • prebiotics especially chosen from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, acacia-type gums for example, or one of their mixtures.
  • the oligosaccharide comprises at least one fructooligosaccharide.
  • this prebiotic may comprise a mixture of fructooligosaccharide and inulin,
  • phytosterols such as resveratrol
  • a monounsaturated fatty acid according to the invention may be used in combination with at least one additional cosmetic active agent, chosen in particular from vitamins B3, B5, B6, B8, C, E, or PP, carotenoids, curcuminoids, niacin, flavonoids, one or more divalent mineral cation (s), bacteria or bacterial extracts from bacteria Non-photosynthetic and non-fruiting filaments, probiotic microorganisms, in particular lactic acid, prebiotic nutrients or a mixture of probiotic microorganisms and / or a mixture of nutrients prebiotics.
  • additional cosmetic active agent chosen in particular from vitamins B3, B5, B6, B8, C, E, or PP, carotenoids, curcuminoids, niacin, flavonoids, one or more divalent mineral cation (s), bacteria or bacterial extracts from bacteria
  • non-photosynthetic and non-fruiting filaments probiotic microorganisms, in particular lactic acid, prebiotic nutrients or a mixture of probiotic micro
  • an antioxidant complex comprising vitamins C and E, and at least one carotenoid, in particular a carotenoid chosen from ⁇ -carotene, lycopene and derivatives (cis-lycopene, lactolycopene), astaxanthin, zeaxanthin and lutein or compounds containing it such as wolfberry or lactowolfberry, flavonoids such as catechins, hesperidin, proanthocyanidins and anthocyanins, resveratrol, cocoa or lactocacao, pomegranate, emblica.
  • a composition of the invention may contain, in addition, one or more divalent mineral cation (s) in different forms.
  • a divalent mineral cation may thus be in the form of an inorganic or organic, anhydrous or hydrated salt or a chelated complex.
  • These salts can be, for example, carbonates, bicarbonates, sulphates, glycerophosphates, chlorides, nitrates, acetates, hydroxides, oxides, salts of ⁇ -hydroxy acids (citrates, tartrates, lactates, malates) or of fruit acids, or salts of amino acids (aspartate, arginate, fumarate) or salts of fatty acids (palmitate, oleate, caseinate, behenate).
  • a divalent mineral cation may be selected from manganese, copper and / or zinc or from alkaline earth.
  • alkaline-earth metal used in the invention mention may be made of barium, calcium, magnesium, strontium and / or beryllium.
  • a divalent mineral cation and in particular an alkaline-earth metal, is used in the present invention in salt form.
  • the salt may be chosen from nitrate, citrate, chloride, gluconate, sulfate, lactate and / or acetate salts.
  • a divalent mineral cation may also be used in the form of a chelated complex, in particular with crystallized or ionized proteins.
  • a divalent inorganic cation may also be in a specific form stored by a microorganism, for example of yeast type, like selenium yeasts.
  • a composition of the invention can contain non-photosynthetic and non-fruiting filamentous bacteria or bacterial extracts derived from non-photosynthetic and non-fruiting filamentous bacteria as defined by the Bergey's Manual of Systemic Bacteriology classification, volume 3, section 23, 9th edition 1989.
  • Beggiatoales and especially bacteria belonging to the genus Beggiotoa.
  • bacteria belonging to the genus Vitreoscilla close to the genus Beggiatoa.
  • the usable bacteria there may be mentioned, for example, Vitreoscilla beggiatoides (ATCC 43181) and Beggiatoa alba (ATCC33555), and preferably the use of the extract of Vitreoscilla filiformis, with in particular the ATCC 15551 strain, its metabolites and its fractions. may be used.
  • a composition of the invention may further comprise at least one probiotic microorganism, a prebiotic or a mixture of probiotic microorganisms and a mixture of prebiotics.
  • probiotic microorganisms suitable for the invention are Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Short Bifidobacterium, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium pseudocatenulatum, Lactobacillus acidophilus (LC1, NCFB 1748); Lactobacillus amylovorus, Lactobacillus breis (Shirota), Lactobacillus rhamnosus (GG strain), Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus delbrueckii (subsp.
  • Lactobacillus fermentum Lactobacillus helveticus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus alimentarius, Lactobacillus curvatus, Lactobacillus casei subsp. casei, Lactobacillus sake Lactococcus lactis, Enterococcus faecalis or faecium, Lactococcus lactis subsp.
  • lactis or cremoris Leuconostoc mesenteroides subsp. dextranicum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. thermophilus, Streptococcus thermophilus, Staphylococcus carnosus, Staphylococcus xylosus, Saccharomyces (cerevisiae or boulardii), Bacillus (cereus var. toyo or subtilis), Bacillus coagulans, Bacillus licheniformis, Escherichia coli strain nissle, Propionibacterium freudenreichii, and mixtures thereof.
  • microorganisms may be formulated as powders, i.e., in a dry form, or as suspensions or solutions.
  • probiotic microorganisms selected from microorganisms of the genus Lactobacillus sp. and / or Bifidobacterium sp., one of their fractions and / or one of their metabolites.
  • Lactobacillus johnsonii Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breva, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum, and mixtures thereof.
  • the most suitable species are Lactobacillus johnsonii, Lactobacillus paracasei, Bifidobacterium adolescentis, Bifidobacterium longum and Bifidobacterum Lactis NCC 2818 (also designated Bbl2 ATCC 27536) respectively deposited according to the Budapest Treaty with the Institut Pasteur (28 rue du Dondel Roux, F -75024 Paris cedex 15) the 30/06/92, 12/01/99, 15/04/99, 15/04/99, 07/06/05 under the following designations CNCM 1-1225, CNCM 1-2116, CNCM 1-2168 and CNCM 1-2170 and CNCM 1-3446, and the genus Bifidobacterium longum (BB536).
  • the strain of Bifidobacterium lactis CNCM 1-3446 can be obtained from Hansen (Hansen A / S Chr., 10-12 Boege Aile, PO Box 407, DK-2970 Hoersholm, Denmark).
  • the composition comprises at least two different microorganisms, including probiotics, and / or metabolites and / or fractions thereof.
  • microorganisms may differ by their nature for example bacterium and fungus, or by their family, their genus, their species, or only by their stock.
  • Prebio ticks suitable for the invention may be selected from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, gums, acacia type, example, or a mixture thereof. More particularly, the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic may comprise a mixture of fructo-oligosaccharide and inulin.
  • a composition of the invention may furthermore advantageously contain polyunsaturated fatty acids, chosen especially from acides-3 fatty acids and ⁇ -6 fatty acids.
  • the unsaturated fatty acids that are suitable for the invention may be chosen from fatty acids containing from 18 to 22 carbon atoms, in particular polyunsaturated fatty acids, and in particular fatty acids ⁇ -3 and ⁇ -6.
  • polyunsaturated fatty acids of the ⁇ -6 series that may be used in a composition of the invention, mention may be made in particular of linoleic acid with 18 carbon atoms and two unsaturations (18: 2, ⁇ -6), the acid ⁇ -linolenic with 18 carbon atoms and three unsaturations (18: 3, ⁇ -6), di-homogamalinolenic acid with 20 carbon atoms and 3 unsaturations (20: 3, ⁇ -6), arachidonic acid, 5,8,11,14 eicosatetraenoic acid (20: 4, ⁇ -6), and docosateetenoic acid (22: 4, ⁇ -6).
  • the polyunsaturated fatty acids of the ⁇ -3 series may especially be chosen from ⁇ -linolenic acid (18: 3, ⁇ -3), stearidonic acid (18: 4, ⁇ -3), acid 5, 8,11,14,17-eicosapentaenoic or EPA (20: 5, ⁇ -3), and 4,7,10,13,16,19-docosaheaxaenoic acid or DHA (22: 6, ⁇ -3), docosapentanoic acid (22.5, ⁇ -3), n-butyl-5, 11,14-eicosatrienonic acid.
  • Particularly suitable for the invention are ⁇ -linolenic acid, ⁇ -linolenic acid, stearidonic acid, eicosapentaenoic acid, docosahexaenoic acid, mixtures thereof or extracts containing them.
  • the sources of ⁇ -linolenic acid may be chosen from vegetable oils such as, for example, evening primrose, borage, blackcurrant seed, echium and hemp, and extracts of the spirulina microalgae (Spirulina maxima and Spirulina platensis).
  • Vegetable oils of nuts, hazelnuts, almonds (Juglans regia), coriander and soy (Glycina max), rapeseed (Brassica naptus), chia, flax, muscat rose and fish oils, for example, are rich in polyunsaturated fatty acids of the ⁇ -3 series. Polyunsaturated fatty acids ⁇ -3 can also be found in zooplankton, crustaceans / molluscs and fish.
  • Microalgae biomass can also be a raw material extraction of ins-3 unsaturated fatty acids.
  • a polyunsaturated fatty acid can be used in a composition of the invention in the form of at least one oil chosen from evening primrose, borage, blackcurrant seed, walnut, soya, fish, sunflower, sprouts of wheat, hemp, fenugreek, musk rose, echium, argan, baobab, rice bran, sesame, almond, walnut, hazelnut, chia, flax, muscat rose, olive, avocado, safflower, coriander and / or microalgae biomass extract (eg spirulina), or zooplankton extracts.
  • a composition of the invention may comprise additional hydrophilic active agents.
  • hydrophilic active agents it is possible to use proteins or protein hydrolysates, amino acids, and especially C 2 -C 10 polyols such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, bacterial or plant extracts such as Aloe Vera.
  • C 2 -C 10 polyols such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, bacterial or plant extracts such as Aloe Vera.
  • composition of the invention may further comprise a lipophilic active agent.
  • retinol vitamin A
  • tocopherol vitamin E
  • ceramides essential oils
  • the active agents according to the invention can be combined with active agents intended, in particular, for the prevention and / or treatment of cutaneous affections.
  • an anti-inflammatory valence such as hesperidin, lactoferrin,
  • the present invention relates to a method of cosmetic treatment orally of the complexion of the skin, and / or associated aesthetic skin disorders, which can be implemented in particular by administering the cosmetic compositions such as defined above, according to the usual technique of use of these compositions.
  • the invention relates to an oral cosmetic method useful for preventing and / or treating imperfections of the complexion of the skin in an individual in need comprising at least one step of administration to said individual of at least one an effective amount of a mono-unsaturated fatty acid, one of its salts and / or one of its esters, and in particular petroselenic acid.
  • a method according to the invention may comprise a step consisting in observing a reduction or even a disappearance of imperfections of the complexion of the skin.
  • a method of the invention may preferably be applied to an elderly individual, an adult woman, an individual having Asian-type skin or an individual having African-type skin.
  • the application of a method of the invention can reduce or even eliminate impurities from the skin, and preferably from the skin of the face, to restore a uniform, unified complexion and / or lacking a dull appearance. , and promote a radiant complexion.
  • a cosmetic process according to the invention can be implemented, in particular, by administering a food composition as defined above.
  • a method of the invention may be implemented daily for example, for example for a single administration per day or administration twice a day, for example once in the morning and once in the evening.
  • a cosmetic process according to the invention can be implemented by oral administration, for example by daily administration of a composition formulated for example in the form of capsules, gels, lotions, dragees, emulsions, tablets, capsules or drinkable ampoules, in quantity. and adequate numbers, depending on their form.
  • An effective amount of monounsaturated fatty acid can be administered in a single dose per day or in divided doses over the day, for example two to three times a day.
  • a method according to the invention may advantageously comprise a single administration.
  • a cosmetic process of the invention may be implemented over a period of time varying from one week to several weeks, or even several months, this period being able to be repeated after periods of non-treatment, for several months or even several years. .
  • an active ingredient according to the invention may be repeated, for example, 2 to 3 times a day, or more, and generally over an extended period of at least 4 weeks, or even 4 to 15 weeks, with if necessary one or more periods of interruption.
  • An oral cosmetic process can be implemented over a period of time ranging from one week to several weeks, or even several months, this period being able to be repeated after periods of non-treatment, for several months or even years.
  • the oral administration of a monounsaturated fatty acid according to the invention can be carried out at the rate of, for example, 3 times a day more, generally over an extended period of at least 4 weeks. or 4 to 15 weeks, including or not one or more periods of interruption or being repeated after a period of interruption.
  • percentages are percentages by weight and ranges of values in the form "between ... and " include the specified lower and upper bounds.
  • the ingredients are mixed, before they are shaped, in the order and under conditions easily determined by those skilled in the art.
  • compositions for the oral route are provided.
  • One to three of these capsules can be taken daily.
  • Example 1D Formulation of the dragée type
  • This type of dragee can be taken 1 to 3 times a day.
  • Example 1E Formulation of the dragée type
  • This type of dragee can be taken 1 to 3 times a day.
  • the daily intake of such a dragee for about a week can significantly reduce the dyschromias and give the skin a homogeneous complexion, bright and radiant.

Abstract

The invention relates to the oral cosmetic or nutraceutical use of an effective amount of at least one monounsaturated fatty acid, of a salt thereof and/or of an ester thereof, as an active agent for treating and/or preventing skin complexion imperfections.

Description

Acide gras monoinsaturé pour prévenir et/ou traiter les imperfections du teint de la peau  Monounsaturated fatty acid to prevent and / or treat imperfections of skin tone
La présente invention concerne le domaine des produits cosmétiques et/ou dermatologiques et des compléments alimentaires destinés au soin du teint de la peau.  The present invention relates to the field of cosmetic and / or dermatological products and dietary supplements intended for the care of the complexion of the skin.
Plus particulièrement, la présente invention propose l'utilisation d'un nouvel actif pour traiter et/ou prévenir les défauts cutanés esthétiques du teint de la peau. La présente invention concerne également des procédés convenant au traitement et/ou à la prévention des imperfections et inhomogénéités du teint de la peau.  More particularly, the present invention proposes the use of a new active agent for treating and / or preventing aesthetic skin defects of the complexion of the skin. The present invention also relates to methods suitable for the treatment and / or prevention of imperfections and inhomogeneities of the complexion of the skin.
De nombreux facteurs peuvent générer des imperfections au niveau de la peau et de son teint. Ces imperfections du teint de la peau sont une cause de plus en plus fréquente de consultations auprès de centres de soins esthétiques ou de cabinets dermatologiques.  Many factors can cause imperfections in the skin and skin tone. These imperfections of the complexion of the skin are a cause more and more frequent of consultations near centers of esthetic care or dermatological practices.
Parmi les facteurs extrinsèques susceptibles d'affecter le teint de la peau, on peut citer l'exposition au soleil, l'exposition aux variations de températures et/ou d'humidité, l'exposition aux polluants ou à la fumée de cigarette. Parmi les facteurs intrinsèques affectant le teint de la peau, on peut citer le stress, la fatigue, des changements hormonaux, une déshydratation de l'épiderme, une altération de la fonction barrière de la peau, le vieillissement ou une sécrétion excessive de sébum.  Extrinsic factors that may affect skin tone include exposure to the sun, exposure to temperature and / or humidity changes, exposure to pollutants or cigarette smoke. Intrinsic factors that affect skin tone include stress, fatigue, hormonal changes, dehydration of the skin, impaired skin barrier function, aging, or excessive secretion of sebum.
Qui plus est, des facteurs génétiques peuvent affecter la sensibilité des individus aux conditions extérieures susceptibles d'affecter le teint de la peau.  Moreover, genetic factors can affect the sensitivity of individuals to external conditions that may affect the skin's complexion.
Ainsi, certaines ethnies, par exemple d'origine asiatique ou africaine, présentent une peau dont le grain est plus sensible et dont le teint peut être plus facilement, ou de manière plus intense, altéré par des conditions extérieures telles que la pollution et la fumée de cigarette. Il en va de même chez les personnes âgées.  Thus, some ethnic groups, for example of Asian or African origin, have a skin whose grain is more sensitive and whose complexion can be more easily, or more intensely, altered by external conditions such as pollution and smoke. of cigarette. The same goes for the elderly.
Ces différents facteurs tendent à brouiller le teint, le rendre inhomogène, terne, cireux ou jaunâtre et à provoquer, voire favoriser, la présence d'impuretés cutanées ou de dyschromies.  These various factors tend to blur the complexion, make it inhomogeneous, dull, waxy or yellowish and to provoke or even favor the presence of cutaneous impurities or dyschromias.
Sous leur forme la plus légère ces imperfections concernent presque chaque individu, et leur fréquence est maximale à l'âge de la puberté. Toutefois, elles peuvent se manifester dès l'âge de 7 à 9 ans et perdurer jusqu'à des âges dépassant 40 ans, et notamment aller au-delà de 60 ans. Ainsi, il est fréquent d'avoir des imperfections au niveau du teint de la peau, notamment du visage, telle qu'un teint brouillé, terne et/ou inhomogène encore après 25 ans. Sous leur forme la plus légère, ces imperfections du teint peuvent se manifester principalement par un teint brouillé, terne ou inhomogène, la présence de dyschromies ou d'impuretés. In their lightest form these imperfections concern almost every individual, and their frequency is maximal at the age of puberty. However, they can manifest themselves from the age of 7 to 9 years and persist until ages over 40 years, including going beyond 60 years. Thus, it is common to have imperfections in the complexion of the skin, especially the face, such as a dull, dull complexion and / or still inhomogeneous after 25 years. In their lightest form, these imperfections of the complexion can be manifested mainly by a dull, dull or inhomogeneous complexion, the presence of dyschromias or impurities.
Sous leur forme la plus grave, ces altérations peuvent avoir, parfois, des conséquences psychosociales invalidantes, susceptibles de conduire à l'isolement, voire à une dépression ou au chômage des individus qui en sont affectés.  In their most serious form, these alterations can sometimes have disabling psychosocial consequences that can lead to the isolation or even depression or unemployment of the individuals who are affected.
Il existe donc un réel besoin d'être en mesure de prévenir, de réduire ou de traiter ces imperfections du teint de la peau.  There is therefore a real need to be able to prevent, reduce or treat these blemishes of the complexion of the skin.
Il demeure également un besoin de disposer de nouveaux actifs susceptibles d'exercer une action efficace et bénéfique sur les imperfections du teint de la peau.  There is also a need for new assets that can have an effective and beneficial effect on the imperfections of skin tone.
La présente invention a pour objet de satisfaire ces besoins.  The object of the present invention is to satisfy these needs.
Ainsi, selon un premier de ses aspects, la présente invention concerne une utilisation cosmétique orale ou nutraceutique d'une quantité efficace d'au moins un acide gras mono-insaturé, d'un de ses sels et/ou d'un de ses esters, à titre d'actif pour traiter et/ou prévenir les imperfections du teint de la peau.  Thus, according to a first aspect, the present invention relates to an oral or nutraceutical cosmetic use of an effective amount of at least one monounsaturated fatty acid, a salt thereof and / or an ester thereof. , as an active ingredient to treat and / or prevent imperfections of the complexion of the skin.
Les acides gras mono-insaturés ont été décrits pour différentes applications, telles que l'hydratation de la peau sèche dans EP 0 709 084 ou le traitement des pellicules et des démangeaisons du cuir chevelu dans EP 0 116 439.  Monounsaturated fatty acids have been described for various applications, such as the hydration of dry skin in EP 0 709 084 or the treatment of dandruff and itching of the scalp in EP 0 116 439.
WO 01/08651 décrit une composition comprenant de l'acide pétrosélinique pour contrôler la sécrétion de sébum et éclaircir le teint de la peau.  WO 01/08651 discloses a composition comprising petroselinic acid for controlling the secretion of sebum and lightening the complexion of the skin.
US 4,097,604 indique qu'un sel de différents acides gras est actif contre les pathogènes de la cavité buccale, permettant ainsi de diminuer l'incidence de ces bactéries sur d'apparition de periodontoses. L'action de ces acides gras est donc limitée à la flore buccale.  US 4,097,604 indicates that a salt of different fatty acids is active against pathogens of the oral cavity, thereby reducing the incidence of these bacteria on the occurrence of periodontoses. The action of these fatty acids is therefore limited to the oral flora.
EP 0 355 842 décrit une crème de soin destinée à prévenir la pigmentation causée par une surproduction de mélanine, ladite crème pouvant renfermer de l'acide pétrosélinique.  EP 0 355 842 discloses a care cream intended to prevent pigmentation caused by an overproduction of melanin, said cream possibly containing petroselinic acid.
EP 1 013 178 décrit l'utilisation d'acide pétrosélinique comme agent anti- inflammatoire et pour traiter les signes cutanés du vieillissement, tels que les rides, la peau flasque, et les taches de sénescence.  EP 1 013 178 discloses the use of petroselinic acid as an anti-inflammatory agent and for treating the skin signs of aging, such as wrinkles, flabby skin, and senescence patches.
WO 99/47110 décrit une méthode cosmétique destinée à améliorer l'apparence de la peau utilisant de l'acide pétrosélinique. US 6,022,890 décrit une composition comprenant un alpha hydroxyacide, de l'acide pétrosélinique et un véhicule cosmétiquement acceptable. WO 99/47110 discloses a cosmetic method for improving the appearance of skin using petroselinic acid. No. 6,022,890 describes a composition comprising an alpha hydroxy acid, petroselinic acid and a cosmetically acceptable vehicle.
Cependant, aucun de ces documents ne laissait présager que l'administration d'une quantité efficace d'un acide gras mono-insaturé, notamment de l'acide pétrosélinique, à un individu en ayant besoin pouvait se révéler être particulièrement efficace pour prévenir et/ou traiter les imperfections du teint de la peau.  However, none of these documents suggested that administering an effective amount of a monounsaturated fatty acid, including petroselinic acid, to an individual in need may be particularly effective in preventing and / or or treat imperfections of the complexion of the skin.
Les inventeurs ont pu mettre en évidence que les acides gras mono-insaturés, notamment l'acide pétrosélinique, conduisent à restaurer un tissu cutané normal en parfaite homéostasie présentant un teint radieux, jeune et en bonne santé.  The inventors have been able to demonstrate that monounsaturated fatty acids, in particular petroselinic acid, lead to the restoration of normal skin tissue in perfect homeostasis with a radiant, young and healthy complexion.
Ainsi, un individu traité selon l'invention, peut voir avantageusement les imperfections du teint de sa peau se réduire, voire disparaître. Le teint de la peau peut devenir homogène, sans dyschromie, sans aspect terne, et dénué d'impureté.  Thus, an individual treated according to the invention can advantageously see the imperfections of the complexion of his skin reduce or even disappear. The complexion of the skin can become homogeneous, without dyschromism, without dull aspect, and devoid of impurity.
Avantageusement encore, l'invention permet de conférer au teint de la peau, notamment de la peau du visage, un aspect radieux et éclatant.  Advantageously, the invention makes it possible to give the complexion of the skin, in particular of the skin of the face, a radiant and radiant appearance.
Au sens de l'invention, on entend désigner par le terme « peau », l'ensemble de la peau d'un individu, en particulier d'un être humain, et plus particulièrement la peau du visage, du cou et du décolleté. Le terme « peau » inclut les surfaces couvertes de poils.  For the purposes of the invention, the term "skin" is intended to denote the entire skin of an individual, in particular a human being, and more particularly the skin of the face, neck and décolleté. The term "skin" includes surfaces covered with hair.
De manière préférée, l'invention convient plus particulièrement au soin de la peau du visage, du cou et du décolleté, et de préférence au soin de la peau du visage.  Preferably, the invention is more particularly suitable for the care of the skin of the face, neck and décolleté, and preferably for the care of the skin of the face.
Selon encore un autre de ses aspects, la présente invention a pour objet un procédé de traitement cosmétique par voie orale, utile pour traiter et/ou prévenir les imperfections du teint de la peau chez un individu en ayant besoin, comprenant au moins une étape d'administration audit individu d'une quantité efficace d'au moins un acide gras mono-insaturé, un de ses sels et/ou un de ses esters.  According to yet another of its aspects, the present invention relates to an oral cosmetic treatment method, useful for treating and / or preventing imperfections of skin tone in an individual in need, comprising at least one step of administering to said individual an effective amount of at least one monounsaturated fatty acid, a salt thereof and / or an ester thereof.
La présente invention permet avantageusement de prévenir et/ou traiter des imperfections du teint de la peau.  The present invention advantageously makes it possible to prevent and / or treat imperfections of the complexion of the skin.
Selon un mode de réalisation, l'invention permet avantageusement de prévenir et/ou traiter un teint de la peau brouillée, terne et/ou inhomogène.  According to one embodiment, the invention advantageously makes it possible to prevent and / or treat a dull, dull and / or inhomogeneous skin complexion.
Selon un autre mode de réalisation, l'invention permet avantageusement de prévenir et/ou traiter des imperfections du teint de la peau, choisies parmi des boutons, des dartres, des dyschromies ou des points noirs. Selon un autre mode de réalisation, une utilisation conforme à l'invention permet avantageusement de prévenir et/ou traiter un teint cireux, jaunâtre, voire maladif. According to another embodiment, the invention advantageously makes it possible to prevent and / or treat imperfections in the complexion of the skin, chosen from pimples, scabs, dyschromias or blackheads. According to another embodiment, a use according to the invention advantageously makes it possible to prevent and / or treat a waxy, yellowish or even sickly complexion.
Une mise en œuvre d'un acide gras mono-insaturé selon l'invention se fait nécessairement en une quantité efficace, i.e. une quantité permettant à l'acide gras de manifester ses propriétés d'actif au regard des imperfections du teint de la peau à prévenir et/ou traiter.  An implementation of a monounsaturated fatty acid according to the invention is necessarily in an effective amount, ie an amount allowing the fatty acid to show its active properties with regard to imperfections of the complexion of the skin to prevent and / or treat.
Au sens de la présente invention, on entend par « prévenir » le fait de réduire à un degré moindre le risque ou la probabilité de manifestation d'un phénomène donné, i.e. dans la présente invention une imperfection du teint de la peau.  Within the meaning of the present invention, the term "prevent" means reducing to a lesser degree the risk or the probability of manifestation of a given phenomenon, i.e. in the present invention an imperfection of the complexion of the skin.
Acide gras mono-insaturé Monounsaturated fatty acid
On entend par « acide gras mono-insaturé » au sens de la présente invention, un acide gras dont la chaîne hydrocarbonée comprend une unique double liaison.  The term "monounsaturated fatty acid" in the sense of the present invention, a fatty acid whose hydrocarbon chain comprises a single double bond.
Il s'agit plus particulièrement d'acides gras à longues chaînes hydrocarbonées. Les acides gras mono-insaturés convenant à l'invention sont notamment les acides gras mono-insaturés comportant une chaîne hydrocarbonée contenant de 12 à 22 atomes de carbone.  It is more particularly fatty acids with long hydrocarbon chains. The monounsaturated fatty acids that are suitable for the invention are, in particular, monounsaturated fatty acids containing a hydrocarbon chain containing from 12 to 22 carbon atoms.
Les acides gras mono-insaturés convenant à l'invention peuvent être mis en oeuvre sous forme acide, ou de sel ou encore sous forme de dérivés notamment d'esters et d'amides d'acides gras.  The monounsaturated fatty acids that are suitable for the invention can be used in acid form, or in the form of a salt, or else in the form of derivatives, in particular fatty acid esters and amides.
Lorsqu'ils se présentent sous forme de sels, les acide gras mono-insaturés de l'invention sont plus particulièrement de sels cosmétiquement acceptables, c'est-à-dire, de sels inorganiques, tels que des sels d'ammonium ou de métaux alcalins, comme le lithium, le potassium, le sodium, des sels d'alcalino-terrreux, comme le magnésium, ou le calcium, ou des sels d'aluminium.  When in the form of salts, the monounsaturated fatty acids of the invention are more particularly cosmetically acceptable salts, that is to say, inorganic salts, such as ammonium or metal salts. alkaline, such as lithium, potassium, sodium, alkaline earth salts, such as magnesium, or calcium, or aluminum salts.
En particulier, les acides gras mono-insaturés convenant à l'invention peuvent se présenter sous forme de sels de calcium.  In particular, the monounsaturated fatty acids that are suitable for the invention may be in the form of calcium salts.
Lorsqu'ils se présentent sous forme d'esters, les acides gras mono-insaturés de l'invention peuvent être estérifïés avec le glycérol sous forme de mono-, di- ou tri-acyl, avec un alcool comme les alcools méthylique et éthylique, avec un sucre, notamment un mono ou un disaccharide, un tocophérol, un tocotriénol, un stérol, comme le cholestérol ou un phytostérol, comme le β-sitostérol, ou encore avec un alcool gras, notamment en Cs Il est entendu que le choix des acides gras mono-insaturés de l'invention est effectué en tenant compte de la finalité de la composition les comportant. When they are in the form of esters, the monounsaturated fatty acids of the invention can be esterified with glycerol in the form of mono-, di- or tri-acyl, with an alcohol such as methyl and ethyl alcohols, with a sugar, in particular a mono or a disaccharide, a tocopherol, a tocotrienol, a sterol, such as cholesterol or a phytosterol, such as β-sitosterol, or with a fatty alcohol, especially in Cs It is understood that the choice of monounsaturated fatty acids of the invention is carried out taking into account the purpose of the composition comprising them.
L'administration d'un acide gras mono-insaturé selon l'invention se fait par voie orale.  The administration of a monounsaturated fatty acid according to the invention is carried out orally.
L'acide gras mono-insaturé de l'invention, son et/ou son ester, peut être mis en œuvre dans une composition par voie orale dans laquelle la teneur dudit acide gras mono-insaturé, son sel et/ou son ester est telle que la dose journalière varie de 0,5 à 2500 mg/j, et notamment de 5 à 500 mg/j.  The mono-unsaturated fatty acid of the invention, its and / or its ester, can be used in an oral composition in which the content of said monounsaturated fatty acid, its salt and / or its ester is such that the daily dose varies from 0.5 to 2500 mg / day, and in particular from 5 to 500 mg / day.
Parmi les acides gras mono-insaturés convenant à l'invention, on utilise particulièrement l'acide oléique ou l'acide pétrosélinique. Convient tout particulièrement à l'invention l'acide pétrosélinique.  Among the monounsaturated fatty acids that are suitable for the invention, oleic acid or petroselinic acid is particularly used. Particularly suitable for the invention is petroselinic acid.
Selon une variante de l'invention, le ou les acides gras mono-insaturés sont utilisés sous une forme isolée, c'est-à-dire après extraction de leur source d'origine.  According to a variant of the invention, the monounsaturated fatty acid or acids are used in an isolated form, that is to say after extraction of their original source.
Selon une autre variante de l'invention, les ou les acides gras mono-insaturés sont utilisés dans un extrait végétal tel qu'une huile.  According to another variant of the invention, the monounsaturated fatty acids or acids are used in a plant extract such as an oil.
Ainsi l'invention se rapporte notamment à l'utilisation cosmétique d'une huile riche en acide gras mono-insaturé de l'invention, et en particulier riche en acide pétrosélinique.  Thus, the invention relates in particular to the cosmetic use of a monounsaturated fatty acid-rich oil of the invention, and in particular rich in petroselinic acid.
Les huiles riches en acide pétrosélinique sont plus particulièrement choisies parmi les huiles d'ombellifère.  The oils rich in petroselinic acid are more particularly chosen from umbelliferous oils.
On entend par huile riche en acide pétrosélinique, une huile comprenant au moins 40 % d'acide prétrosélinique.  Oil rich in petroselinic acid is understood to mean an oil comprising at least 40% of pretroselinic acid.
Les ombellifères sont des plantes dont les fleurs sont disposées en ombelles, les espèces particulièrement riches en acide pétrosélénique sont les Umbellifarea-Apiacea et Araliaceae. Les plantes du genre Thapsia sont également des sources d'acide pétrosélénique (Avato et al, Lipids, 2001, 36, 845).  Umbelliferae are plants whose flowers are arranged in umbels, species particularly rich in petroselenic acid are Umbellifarea-Apiacea and Araliaceae. Plants of the genus Thapsia are also sources of petroselenic acid (Avato et al, Lipids, 2001, 36, 845).
Les espèces de préférence utilisées dans l'invention sont la coriandre, le cerfeuil, la carotte, le céleri, le cumin, le carvi, le persil et l'aneth.  The preferred species used in the invention are coriander, chervil, carrot, celery, caraway, caraway, parsley and dill.
L'huile d'ombellifère utilisée selon l'invention peut être extraite de la graine d'une ombellifère, par exemple par broyage ou pressage, puis raffinage. L'huile d'ombellifère a une teneur en acide pétrosélinique qui varie selon la graine d'ombellifère d'où elle est extraite. Pour une même ombellifère, la teneur en acide pétrosélinique varie aussi selon le pays d'origine de lOmbellifère et selon l'extraction qui peut être plus ou moins complète. The umbelliferous oil used according to the invention can be extracted from the seed of an umbellifer, for example by grinding or pressing, then refining. Umbellifer oil has a petroselinic acid content that varies according to the umbelliferous seed from which it is extracted. For the same umbellifer, the petroselinic acid content also varies according to the country of origin of the Ombellifer and according to the extraction which can be more or less complete.
L'acide pétrosélénique est également un composé abondant (environ 48 %) de l'huile de graine de Gernium sanguneum (Tsevegsuren et al., Lipids, 2004, 39, 571).  Petroselenic acid is also an abundant (about 48%) compound of Gernium sanguneum seed oil (Tsevegsuren et al., Lipids, 2004, 39, 571).
Selon un mode de réalisation, l'acide gras mono-insaturé plus particulièrement considéré dans l'invention est l'acide pétrosélénique.  According to one embodiment, the monounsaturated fatty acid more particularly considered in the invention is petroselenic acid.
En particulier, l'acide pétrosélénique peut être utilisé sous forme d'huile d'ombellifère ou de Gernium sanguneum.  In particular, petroselenic acid can be used in the form of umbelliferous oil or Gernium sanguneum.
Selon un autre mode de réalisation, l'huile d'ombellifère plus particulièrement considérée dans l'invention peut être choisie parmi les huiles de graines de coriandre, de cerfeuil, de carotte, de céleris, de cumin, de carvi, de persil, d'aneth, et leurs mélanges. Applications  According to another embodiment, the umbelliferous oil more particularly considered in the invention can be chosen from coriander, chervil, carrot, celery, caraway, caraway, parsley, d dill, and mixtures thereof. applications
L'invention permet d'améliorer, d'homogénéiser ou de restaurer le teint de la peau.  The invention makes it possible to improve, homogenize or restore the complexion of the skin.
Selon un mode de réalisation cosmétique, l'invention vise à prévenir et/ou traiter les imperfections du teint de la peau.  According to a cosmetic embodiment, the invention aims to prevent and / or treat imperfections of the complexion of the skin.
Au sens de l'invention on entend par « imperfections du teint de la peau », une altération de l'aspect naturel d'une peau en bonne santé.  For the purposes of the invention, the term "imperfections of the complexion of the skin" means an alteration of the natural appearance of a healthy skin.
Les imperfections du teint de la peau considérées dans l'invention n'incluent pas les altérations de la peau résultant de phénomènes inflammatoires telles que des rougeurs inflammatoires.  The imperfections of the complexion of the skin considered in the invention do not include the alterations of the skin resulting from inflammatory phenomena such as inflammatory redness.
Les imperfections du teint de la peau considérées dans l'invention n'incluent pas les défauts cutanés liés à une surproduction de mélanine.  The imperfections of the complexion of the skin considered in the invention do not include skin defects related to overproduction of melanin.
Les imperfections du teint de la peau considérées dans l'invention n'incluent pas les défauts de surface de la peau, tels que les rugosités ou les crevasses.  The imperfections of skin tone considered in the invention do not include skin surface defects, such as roughness or crevices.
Les imperfections du teint de la peau au sens de l'invention n'incluent pas les défauts de clarté du teint et la mise en œuvre de l'invention ne vise pas à éclaircir le teint de la peau ou à blanchir la peau.  The imperfections of the complexion of the skin within the meaning of the invention do not include the defects of clarity of the complexion and the implementation of the invention is not intended to lighten the complexion of the skin or to whiten the skin.
Plus particulièrement, les imperfections du teint de la peau considérées par l'invention peuvent, notamment, être choisies parmi les peaux brouillées, les peaux ternes, les peaux à teint inhomogène, ou les peaux présentant des impuretés ou des dyschromies. In particular, imperfections of the complexion of the skin considered by the invention may, in particular, be chosen from scrambled skins, dull skins, hides with an inhomogeneous complexion, or skins presenting impurities or dyschromias.
Au sens de l'invention, on entend par « impuretés de la peau », kystes, comédons, lésions cicatricielles avec ou sans dyschromie.  For the purposes of the invention, the term "impurities of the skin", cysts, comedones, cicatricial lesions with or without dyschromia.
Plus particulièrement, la mise en œuvre d'un acide gras mono-insaturé selon l'invention permet de révéler l'éclat du teint.  More particularly, the implementation of a monounsaturated fatty acid according to the invention makes it possible to reveal the radiance of the complexion.
Au sens de l'invention, « révéler l'éclat du teint de la peau » ne peut en aucune manière être assimilé à une action visant à éclaircir le teint de la peau. Au sens de l'invention, l'éclat du teint de la peau manifeste la radiance naturelle du teint de la peau caractéristique des peaux jeunes et en bonne santé.  For the purposes of the invention, "revealing the radiance of the complexion of the skin" can in no way be equated with an action to lighten the skin's complexion. For the purposes of the invention, the radiance of the complexion of the skin shows the natural radiance of the complexion of the skin characteristic of young and healthy skin.
Ainsi, l'invention permet de conférer un teint de peau moins terne, moins brouillé et moins gris, et plus éclatant.  Thus, the invention makes it possible to confer a skin tone less dull, less scrambled and less gray, and more radiant.
Galé nique Galé
Les compositions selon l'invention sont administrées par voie orale. Les compositions selon l'invention peuvent se présenter sous toutes les formes galéniques normalement utilisées selon la voie d'utilisation.  The compositions according to the invention are administered orally. The compositions according to the invention may be in any of the galenical forms normally used according to the route of use.
Une composition selon l'invention comprend un milieu physio logiquement ou pharmaceutiquement acceptable.  A composition according to the invention comprises a physiologically or pharmaceutically acceptable medium.
La voie orale et/ou parentérale a l'avantage d'agir de façon plus globale sur l'ensemble de la peau et dans ces couches profondes. The oral and / or parenteral route has the advantage of acting more generally on the entire skin and in these deep layers.
Par « composition pour voie orale », on entend, par exemple, des compositions nutritionnelles, nutraceutiques, ou cosméceutiques, comprenant au moins un acide gras mono-insaturé selon l'invention, un de ses sels et/ou un de ses esters.  By "composition for the oral route" is meant, for example, nutritional, nutraceutical or cosmeceutical compositions, comprising at least one monounsaturated fatty acid according to the invention, one of its salts and / or one of its esters.
Dans le cas d'une composition convenant à une administration par voie orale, on privilégie l'utilisation d'un support ingérable. Le support ingérable peut être de nature diverse selon le type de composition considérée.  In the case of a composition suitable for oral administration, the use of an ingestible carrier is preferred. The unmanageable support may be of various nature depending on the type of composition considered.
Pour l'ingestion, de nombreuses formes de réalisation de compositions orales et notamment de compléments alimentaires sont possibles.  For ingestion, many embodiments of oral compositions and in particular dietary supplements are possible.
La formulation de telles compositions peut être réalisée par tout procédé usuel connu de l'homme de l'art pour produire, par exemple, des solutions buvables, des dragées, des gélules, des gels, des émulsions, des comprimés à avaler ou à croquer, des capsules, notamment des capsules molles ou dures, des granulés à dissoudre, des sirops, des aliments solides ou liquides et des hydrogels permettant une libération contrôlée. The formulation of such compositions can be carried out by any usual method known to those skilled in the art to produce, for example, oral solutions, dragees, capsules, gels, emulsions, swallowing or chewable tablets, capsules, especially soft or hard capsules, granules for dissolving, syrups, solid or liquid foods and hydrogels for controlled release.
Conviennent, par exemple, comme support alimentaire, des comprimés, des gélules ou des tablettes, des suspensions, des suppléments oraux sous forme sèche et des suppléments oraux sous forme liquide.  For example, as a food carrier, tablets, capsules or lozenges, suspensions, oral supplements in dry form and oral supplements in liquid form are suitable.
En particulier, le(s) actif(s) selon l'invention peuvent être incorporés dans toutes formes de compléments alimentaires ou d'aliments enrichis, par exemple des barres alimentaires, ou des poudres compactées ou non. Les poudres peuvent être diluées à l'eau, dans du soda, des produits laitiers ou dérivés du soja, ou être incorporées dans des barres alimentaires.  In particular, the active (s) according to the invention can be incorporated into all forms of food supplements or fortified foods, for example food bars, or compacted powders or not. The powders can be diluted with water, in soda, dairy products or soy derivatives, or incorporated into food bars.
Selon un mode préféré de réalisation, une composition selon l'invention administrée par voie orale peut être formulée sous forme de dragée, de gélule, de gel, d'émulsion, de comprimé, de capsule, d'hydrogel, de barre alimentaire, de poudre compactée ou non, de suspension ou solution liquide, de confiserie, de lait fermenté, de fromage fermenté, de chewing-gum, de pâte dentifrice ou de solution spray.  According to a preferred embodiment, a composition according to the invention administered orally can be formulated in the form of dragee, capsule, gel, emulsion, tablet, capsule, hydrogel, food bar, compacted powder or not, suspension or liquid solution, confectionery, fermented milk, fermented cheese, chewing gum, toothpaste or spray solution.
Conviennent, par exemple, comme supports alimentaires, le lait, le yaourt, le fromage, les laits fermentés, les produits fermentés à base de lait, des glaces, des produits à base de céréales fermentées ou non, des poudres à base de lait, des formules pour enfants et nourrissons, des aliments pour animaux en particulier domestiques, des comprimés ou tablettes, des suspensions de bactéries liquides, des suppléments oraux sous forme sèche et les suppléments oraux sous forme liquide.  Milk, yoghurt, cheese, fermented milks, fermented milk products, ice cream, fermented and non-fermented cereal products, milk-based powders, for example, are suitable as food carriers, formulas for children and infants, especially pet food, tablets or tablets, suspensions of liquid bacteria, oral supplements in dry form and oral supplements in liquid form.
Les compositions par voie orale peuvent se présenter soit sous forme anhydre, soit sous forme aqueuse selon l'indication dermocosmétique.  The oral compositions may be in anhydrous form or in aqueous form according to the dermocosmetic indication.
Les actifs selon l'invention peuvent être formulés avec les excipients et composants usuels pour de telles compositions orales ou compléments alimentaires, à savoir notamment des composants gras et/ou aqueux, des agents humectants, épaississants, conservateurs, des agents de texture, de saveur et/ou d'enrobage, des antioxydants, des conservateurs et des colorants usuels dans le domaine de l'alimentaire.  The active agents according to the invention may be formulated with the excipients and components customary for such oral compositions or food supplements, namely in particular fatty and / or aqueous components, humectants, thickeners, preservatives, texture and flavoring agents. and / or coating, antioxidants, preservatives and dyes customary in the field of food.
Les agents de formulation et excipients pour composition orale, et notamment pour compléments alimentaires sont connus dans ce domaine et ne font pas ici l'objet d'une description détaillée. En particulier, la composition selon l'invention peut être une composition alimentaire pour la consommation humaine. Il peut s'agir en particulier d'aliments complets nutritionnels, de boissons, d'eaux minérales, de soupes, de suppléments diététiques et d'aliments de remplacement ou de substitution, de barres nutritionnelles, de confiseries, de produits à base de lait ou à base de lait fermenté, de yaourts, de poudres à base de lait, de produits de nutrition entérale, de compositions pour enfants et/ou nourrissons, de produits à base de céréales fermentées ou non, de glaces, de chocolat, de café, de produits « culinaires » tels que de la mayonnaise, de la purée de tomate ou des assaisonnements pour salades. The formulating agents and excipients for oral composition, and especially for food supplements, are known in this field and are not the subject of a detailed description here. In particular, the composition according to the invention may be a food composition for human consumption. This may include, in particular, nutritional supplements, beverages, mineral waters, soups, dietary supplements and substitute or substitute foods, nutritional bars, confectionery, milk-based products or based on fermented milk, yogurts, milk-based powders, enteral nutrition products, compositions for children and / or infants, fermented or non-fermented cereal products, ice cream, chocolate, coffee "culinary" products such as mayonnaise, tomato puree or salad dressings.
La composition selon l'invention peut également être destinée aux animaux, notamment aux animaux domestiques, tels que les chats et les chiens, et être formulés sous forme d'aliments ou de compléments alimentaires pour animaux.  The composition according to the invention may also be intended for animals, in particular for domestic animals, such as cats and dogs, and may be formulated as food or feed supplements for animals.
Actif additionnel Additional asset
Un acide gras mono-insaturé selon l'invention peut avantageusement être mis en œuvre en association avec un actif additionnel, notamment cosmétique ou pharmaceutique.  A monounsaturated fatty acid according to the invention may advantageously be used in combination with an additional active ingredient, in particular a cosmetic or pharmaceutical ingredient.
Avantageusement, un tel actif additionnel, cosmétique ou pharmaceutique, peut être destiné à exercer un effet cosmétique, de soin ou d'hygiène sur la peau, les cheveux, les cils, les poils et/ou le cuir chevelu, et préférentiellement sur la peau.  Advantageously, such additional active ingredient, cosmetic or pharmaceutical, may be intended to exert a cosmetic, care or hygiene effect on the skin, the hair, the eyelashes, the hairs and / or the scalp, and preferentially on the skin .
Les actifs additionnels sont choisis par l'homme du métier de sorte à ce qu'ils ne nuisent pas à l'effet des acides gras mono-insaturés de l'invention.  The additional active agents are chosen by those skilled in the art so that they do not interfere with the effect of the monounsaturated fatty acids of the invention.
En particulier, un actif additionnel convenant à l'invention pourra être choisi parmi les actifs destinés à traiter et/ou prévenir les peaux grasses ou à tendance grasse.  In particular, an additional asset that is suitable for the invention may be chosen from active agents intended to treat and / or prevent oily or oily skin.
Selon un autre mode de réalisation, on peut associer à un microorganisme selon l'invention des agents actifs destinés à la prévention et/ou au traitement des affections cutanées.  According to another embodiment, it is possible to associate with a microorganism according to the invention active agents intended for the prevention and / or treatment of cutaneous affections.
A titre d'actif additionnel utilisable, on peut citer : As additional assets that can be used, mention may be made of:
- les vitamines, telles que les vitamines A, B5, B6, B8, C, D, E, ou PP (vitamine B3 ou niacine), - les anti-oxydants, tels que les curcuminoïdes ; les caroténoïdes, notamment un caroténoïde choisi parmi le β-carotène, le lycopène et ses dérivés, tel que le cis- lycopène ou le lactolycopène, l'astaxanthine, la zéaxanthine et la lutéine ou les composés en contenant comme le wolfberry ou la lactowolfberry ; des composés polyphénols, les flavonoïdes tels que les catéchines ; l'hespéridine, les proanthocyanidines, les anthocyanines, les OPC (oligomères procyanidoliques) ; les ubiquinones ; les extraits de café contenant des polyphénols et/ou des diterpènes ; les extraits de chicorés ; les extraits de ginkgo biloba ; les extraits de raisins riches en proanthocyanidines ; les extraits de piment ; les extraits de soja ; le cacao ou lactocacao ; la grenade ; l'Emblica, vitamins, such as vitamins A, B5, B6, B8, C, D, E, or PP (vitamin B3 or niacin), antioxidants, such as curcuminoids; carotenoids, in particular a carotenoid chosen from β-carotene, lycopene and its derivatives, such as cis-lycopene or lactolycopene, astaxanthin, zeaxanthin and lutein or the compounds containing them, such as wolfberry or lactowolfberry; polyphenol compounds, flavonoids such as catechins; hesperidin, proanthocyanidins, anthocyanins, OPCs (procyanidolic oligomers); ubiquinones; coffee extracts containing polyphenols and / or diterpenes; chicory extracts; ginkgo biloba extracts; grape extracts rich in proanthocyanidins; chili extracts; soy extracts; cocoa or lactocacao; the grenade ; Emblica,
- les minéraux, tels que le zinc, le calcium, le magnésium, le cuivre, le fer, l'iode, le manganèse, le sélénium, le chrome (III),  minerals, such as zinc, calcium, magnesium, copper, iron, iodine, manganese, selenium, chromium (III),
- les sucres,  - sugars,
- les acides aminés, notamment les acides aminés soufrés, tels que des précurseurs de glutathion, la taurine, les acides aminés du sélénium,  amino acids, especially sulfur-containing amino acids, such as glutathione precursors, taurine, the amino acids of selenium,
- les acides gras polyinsaturés 3 et 6,  polyunsaturated fatty acids 3 and 6,
- des prébiotiques, notamment choisis parmi les oligosaccharides, produits à partir du glucose, galactose, xylose, maltose, sucrose, lactose, amidon, xylane, l'hémicellulose, l'inuline, les gommes de type acacia par exemple, ou un de leurs mélanges. Plus particulièrement, l'oligosaccharide comprend au moins un fructo-oligosaccharide. Plus particulièrement, ce prébiotique peut comprendre un mélange de fructo-oligosaccharide et d'inuline,  prebiotics, especially chosen from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, acacia-type gums for example, or one of their mixtures. More particularly, the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic may comprise a mixture of fructooligosaccharide and inulin,
- les phytostérols, comme le resvératrol,  phytosterols, such as resveratrol,
- l'hespéridine,  hesperidin,
- et leurs mélanges.  - and their mixtures.
Selon un mode préféré de réalisation, un acide gras mono-insaturé selon l'invention, un de ses sels et/ou un de ses esters, peut être utilisé en association avec au moins un actif cosmétique additionnel en particulier choisi parmi les vitamines B3, B5, B6, B8, C, E, ou PP, les caroténoïdes, les curcuminoïdes, la niacine, les flavonoïdes, un ou plusieurs cation(s) minéral(aux) divalent(s), des bactéries ou des extraits bactériens issus de bactéries filamenteuses non photosynthétiques et non fructifiantes, des microorganismes probiotiques, en particulier à acide lactique, des nutriments prébiotiques ou un mélange de microorganismes probiotiques et/ou un mélange de nutriments prébiotiques. According to a preferred embodiment, a monounsaturated fatty acid according to the invention, one of its salts and / or one of its esters, may be used in combination with at least one additional cosmetic active agent, chosen in particular from vitamins B3, B5, B6, B8, C, E, or PP, carotenoids, curcuminoids, niacin, flavonoids, one or more divalent mineral cation (s), bacteria or bacterial extracts from bacteria Non-photosynthetic and non-fruiting filaments, probiotic microorganisms, in particular lactic acid, prebiotic nutrients or a mixture of probiotic microorganisms and / or a mixture of nutrients prebiotics.
En particulier, on peut utiliser un complexe anti-oxydant comprenant les vitamines C et E, et au moins un caroténoïde, notamment un caroténoïde choisi parmi le β-carotène, le lycopène et dérivés (cis-lycopène, lactolycopène), l'astaxanthine, la zéaxanthine et la lutéine ou les composés en contenant comme le wolfberry ou lactowolfberry, des flavonoïdes telles que les catéchines, l'hespéridine, des proanthocyanidines et des anthocyanines, le resveratrol, le cacao ou lactocacao, la grenade, l'emblica. Une composition de l'invention peut contenir, en outre, un ou plusieurs cation(s) minéral(aux) divalent(s) sous différentes formes.  In particular, it is possible to use an antioxidant complex comprising vitamins C and E, and at least one carotenoid, in particular a carotenoid chosen from β-carotene, lycopene and derivatives (cis-lycopene, lactolycopene), astaxanthin, zeaxanthin and lutein or compounds containing it such as wolfberry or lactowolfberry, flavonoids such as catechins, hesperidin, proanthocyanidins and anthocyanins, resveratrol, cocoa or lactocacao, pomegranate, emblica. A composition of the invention may contain, in addition, one or more divalent mineral cation (s) in different forms.
Un cation minéral divalent peut ainsi être sous la forme d'un sel minéral ou organique, anhydre ou hydraté ou d'un complexe chelaté. Ces sels peuvent être par exemple des carbonates, des bicarbonates, des sulfates, des glycérophosphates, des chlorures, des nitrates, des acétates, des hydroxydes, des oxydes, des sels d'a- hydroxyacides (citrates, tartrates, lactates, malates) ou d'acides de fruits, ou encore des sels d'acides aminés (aspartate, arginate, fumarate) ou des sels d'acides gras (palmitate, oléate, caséinate, béhénate).  A divalent mineral cation may thus be in the form of an inorganic or organic, anhydrous or hydrated salt or a chelated complex. These salts can be, for example, carbonates, bicarbonates, sulphates, glycerophosphates, chlorides, nitrates, acetates, hydroxides, oxides, salts of α-hydroxy acids (citrates, tartrates, lactates, malates) or of fruit acids, or salts of amino acids (aspartate, arginate, fumarate) or salts of fatty acids (palmitate, oleate, caseinate, behenate).
Un cation minéral divalent peut être choisi parmi le manganèse, le cuivre et/ou le zinc ou parmi les alcalino -terreux. Comme métal alcalino -terreux utilisable dans l'invention, on peut citer le baryum, le calcium, le magnésium, le strontium et/ou le béryllium.  A divalent mineral cation may be selected from manganese, copper and / or zinc or from alkaline earth. As alkaline-earth metal used in the invention, mention may be made of barium, calcium, magnesium, strontium and / or beryllium.
Avantageusement, un cation minéral divalent, et notamment un métal alcalino -terreux, est utilisé dans la présente invention sous forme de sel. En particulier, le sel peut être choisi parmi les sels de nitrate, citrate, chlorure, gluconate, sulfate, lactate et/ou acétate.  Advantageously, a divalent mineral cation, and in particular an alkaline-earth metal, is used in the present invention in salt form. In particular, the salt may be chosen from nitrate, citrate, chloride, gluconate, sulfate, lactate and / or acetate salts.
Un cation minéral divalent peut aussi être utilisé sous la forme d'un complexe chélaté notamment à des protéines cristallisées ou ionisées.  A divalent mineral cation may also be used in the form of a chelated complex, in particular with crystallized or ionized proteins.
Un cation minéral divalent peut encore être sous une forme spécifique stockée par un microorganisme, par exemple de type levure, à l'image des levures séléniées.  A divalent inorganic cation may also be in a specific form stored by a microorganism, for example of yeast type, like selenium yeasts.
Selon un autre mode de réalisation, une composition de l'invention peut contenir des bactéries filamenteuses non photosynthétiques et non fructifiantes ou des extraits bactériens issus de bactéries filamenteuses non photosynthétiques et non fructifiantes telles que définies selon la classification du Bergey's Manual of Systemic Bacteriology, volume 3, section 23, 9ème édition 1989. According to another embodiment, a composition of the invention can contain non-photosynthetic and non-fruiting filamentous bacteria or bacterial extracts derived from non-photosynthetic and non-fruiting filamentous bacteria as defined by the Bergey's Manual of Systemic Bacteriology classification, volume 3, section 23, 9th edition 1989.
On peut citer en particulier les bactéries appartenant à l'ordre des In particular, bacteria belonging to the order of
Beggiatoales, et notamment les bactéries appartenant au genre Beggiotoa. On peut citer par ailleurs les bactéries appartenant au genre Vitreoscilla, proche du genre Beggiatoa. Parmi les bactéries utilisables, on peut citer par exemple, Vitreoscilla beggiatoïdes (ATCC 43181) et Beggiatoa alba (ATCC33555), et préférentiellement l'utilisation de l'extrait de Vitreoscilla filiformis, avec en particulier la souche ATCC 15551, ses métabolites et ses fractions pourront être utilisés. Beggiatoales, and especially bacteria belonging to the genus Beggiotoa. There may also be mentioned bacteria belonging to the genus Vitreoscilla, close to the genus Beggiatoa. Among the usable bacteria, there may be mentioned, for example, Vitreoscilla beggiatoides (ATCC 43181) and Beggiatoa alba (ATCC33555), and preferably the use of the extract of Vitreoscilla filiformis, with in particular the ATCC 15551 strain, its metabolites and its fractions. may be used.
Une composition de l'invention peut, en outre, comprendre au moins un microorganisme probiotique, un prébiotique ou un mélange de microorganismes probiotiques et un mélange de prébiotiques. A composition of the invention may further comprise at least one probiotic microorganism, a prebiotic or a mixture of probiotic microorganisms and a mixture of prebiotics.
Des exemples spécifiques de microorganismes probiotiques convenant à l'invention sont Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium brève, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium pseudocatenulatum, Lactobacillus acidophilus (LC1, NCFB 1748) ; Lactobacillus amylovorus, Lactobacillus casei (Shirota), Lactobacillus rhamnosus (souche GG), Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus delbrueckii (subsp. bulgaricus, lactis), Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus alimentarius, Lactobacillus curvatus, Lactobacillus casei subsp. casei, Lactobacillus sake Lactococcus lactis, Enterococcus faecalis ou faecium, Lactococcus lactis subspp. lactis ou cremoris, Leuconostoc mesenteroides subsp. dextranicum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. thermophilus, Streptococcus thermophilus, Staphylococccus carnosus, Staphylococcus xylosus, Saccharomyces (cerevisiae ou encore boulardiî), Bacillus (cereus var. toyo ou subtilis), Bacillus coagulans, Bacillus licheniformis, Escherichia coli strain nissle, Propionibacterium freudenreichii, et leurs mélanges. Specific examples of probiotic microorganisms suitable for the invention are Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Short Bifidobacterium, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium pseudocatenulatum, Lactobacillus acidophilus (LC1, NCFB 1748); Lactobacillus amylovorus, Lactobacillus breis (Shirota), Lactobacillus rhamnosus (GG strain), Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus delbrueckii (subsp. Bulgaricus, lactis), Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus alimentarius, Lactobacillus curvatus, Lactobacillus casei subsp. casei, Lactobacillus sake Lactococcus lactis, Enterococcus faecalis or faecium, Lactococcus lactis subsp. lactis or cremoris, Leuconostoc mesenteroides subsp. dextranicum, Pediococcus acidilactici, Sporolactobacillus inulinus, Streptococcus salvarius subsp. thermophilus, Streptococcus thermophilus, Staphylococcus carnosus, Staphylococcus xylosus, Saccharomyces (cerevisiae or boulardii), Bacillus (cereus var. toyo or subtilis), Bacillus coagulans, Bacillus licheniformis, Escherichia coli strain nissle, Propionibacterium freudenreichii, and mixtures thereof.
Les microorganismes peuvent être formulés à l'état de poudres, c'est-à-dire sous une forme sèche, ou sous forme de suspensions ou de solutions.  The microorganisms may be formulated as powders, i.e., in a dry form, or as suspensions or solutions.
Plus particulièrement, il peut s'agir de microorganismes probiotiques choisi parmi des microorganismes du genre Lactobacillus sp. et/ou Bifidobacterium sp., l'une de leurs fractions et/ou l'un de leurs métabolites. A titre illustratif de ces microorganismes, on peut plus particulièrement citer les Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei ou Bifidobacterium bifidum, Bifidobacterium brève, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis ou Bifidobacterium pseudocatenulatum, et leurs mélanges.  More particularly, it may be probiotic microorganisms selected from microorganisms of the genus Lactobacillus sp. and / or Bifidobacterium sp., one of their fractions and / or one of their metabolites. As an illustration of these microorganisms, mention may be made more particularly of Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breva, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum, and mixtures thereof.
Les espèces convenant tout particulièrement sont les Lactobacillus johnsonii, Lactobacillus paracasei, Bifidobacterium adolescentis, Bifidobacterium longum et Bifidobacterum Lactis NCC 2818 (encore désigné Bbl2 ATCC 27536) respectivement déposées suivant le traité de Budapest avec l'Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cedex 15) les 30/06/92, 12/01/99, 15/04/99, 15/04/99, 07/06/05 sous les désignations suivantes CNCM 1-1225, CNCM 1-2116, CNCM 1-2168 et CNCM 1-2170 et CNCM 1-3446, et le genre Bifidobacterium longum (BB536). La souche de Bifidobacterium lactis CNCM 1-3446 peut être obtenue chez Hansen (Chr. Hansen A/S, 10-12 Boege Aile, P.O. Box 407, DK-2970 Hoersholm, Danemark).  The most suitable species are Lactobacillus johnsonii, Lactobacillus paracasei, Bifidobacterium adolescentis, Bifidobacterium longum and Bifidobacterum Lactis NCC 2818 (also designated Bbl2 ATCC 27536) respectively deposited according to the Budapest Treaty with the Institut Pasteur (28 rue du Docteur Roux, F -75024 Paris cedex 15) the 30/06/92, 12/01/99, 15/04/99, 15/04/99, 07/06/05 under the following designations CNCM 1-1225, CNCM 1-2116, CNCM 1-2168 and CNCM 1-2170 and CNCM 1-3446, and the genus Bifidobacterium longum (BB536). The strain of Bifidobacterium lactis CNCM 1-3446 can be obtained from Hansen (Hansen A / S Chr., 10-12 Boege Aile, PO Box 407, DK-2970 Hoersholm, Denmark).
Selon un mode de réalisation particulier de l'invention, la composition comprend au moins deux microorganismes différents, notamment probiotiques, et/ou des métabolites et/ou des fractions de ceux-ci. Ces microorganismes peuvent différer par leur nature par exemple bactérie et champignon, ou bien encore par leur famille, leur genre, leur espèce, ou seulement par leur souche.  According to a particular embodiment of the invention, the composition comprises at least two different microorganisms, including probiotics, and / or metabolites and / or fractions thereof. These microorganisms may differ by their nature for example bacterium and fungus, or by their family, their genus, their species, or only by their stock.
Les prébio tiques convenant à l'invention peuvent être choisis parmi les oligosaccharides, produits à partir du glucose, galactose, xylose, maltose, sucrose, lactose, amidon, xylane, l'hémicellulose, l'inuline, des gommes, de type acacia par exemple, ou un de leurs mélanges. Plus particulièrement, l'oligosaccharide comprend au moins un fructo-oligosaccharide. Plus particulièrement, ce prébiotique peut comprendre un mélange de fructo-oligosaccharide et d'inuline. Une composition de l'invention peut contenir en outre, avantageusement, des acides gras polyinsaturés notamment choisis parmi les acides gras ω-3 et les acides gras ω-6. Prebio ticks suitable for the invention may be selected from oligosaccharides, produced from glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, gums, acacia type, example, or a mixture thereof. More particularly, the oligosaccharide comprises at least one fructooligosaccharide. More particularly, this prebiotic may comprise a mixture of fructo-oligosaccharide and inulin. A composition of the invention may furthermore advantageously contain polyunsaturated fatty acids, chosen especially from acides-3 fatty acids and ω-6 fatty acids.
En particulier, les acides gras insaturés convenant à l'invention peuvent être choisis parmi les acides gras comportant de 18 à 22 atomes de carbone, en particulier les acides gras polyinsaturés, et notamment les acides gras ω-3 et ω-6.  In particular, the unsaturated fatty acids that are suitable for the invention may be chosen from fatty acids containing from 18 to 22 carbon atoms, in particular polyunsaturated fatty acids, and in particular fatty acids ω-3 and ω-6.
Parmi les acides gras polyinsaturés de la série ω-6 utilisables dans une composition de l'invention, on peut citer en particulier l'acide linoléique à 18 atomes de carbone et deux insaturations (18:2, ω-6), l'acide γ-linolénique à 18 atomes de carbone et trois insaturations (18:3, ω-6), l'acide di-homogamalinolénique à 20 atomes de carbone et 3 insaturations (20:3, ω-6), l'acide arachidonique, l'acide 5,8,11,14 éicosatétraénoïque (20:4, ω-6), et l'acide docosatétraenoique (22:4, ω-6).  Among the polyunsaturated fatty acids of the ω-6 series that may be used in a composition of the invention, mention may be made in particular of linoleic acid with 18 carbon atoms and two unsaturations (18: 2, ω-6), the acid γ-linolenic with 18 carbon atoms and three unsaturations (18: 3, ω-6), di-homogamalinolenic acid with 20 carbon atoms and 3 unsaturations (20: 3, ω-6), arachidonic acid, 5,8,11,14 eicosatetraenoic acid (20: 4, ω-6), and docosateetenoic acid (22: 4, ω-6).
Les acides gras polyinsaturés de la série ω-3 peuvent notamment être choisis parmi l'acide a-linolénique (18:3, ω-3), l'acide stéaridonique (18:4, ω-3), l'acide 5,8,11,14,17-eicosapentaénoïque ou EPA (20:5, ω-3), et l'acide 4,7,10,13,16,19- docosahéxaénoïque ou DHA (22:6, ω-3), l'acide docosapentanoique (22,5, ω-3), l'acide n-butyl-5 ,11,14-eicosatriènonique.  The polyunsaturated fatty acids of the ω-3 series may especially be chosen from α-linolenic acid (18: 3, ω-3), stearidonic acid (18: 4, ω-3), acid 5, 8,11,14,17-eicosapentaenoic or EPA (20: 5, ω-3), and 4,7,10,13,16,19-docosaheaxaenoic acid or DHA (22: 6, ω-3), docosapentanoic acid (22.5, ω-3), n-butyl-5, 11,14-eicosatrienonic acid.
Conviennent tout particulièrement à l'invention, l'acide α-linolénique, l'acide γ-linolénique, l'acide stéaridonique, l'acide éicosapentaénoïque, l'acide docosahexaénoïque, leurs mélanges ou les extraits les comportant.  Particularly suitable for the invention are α-linolenic acid, γ-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosahexaenoic acid, mixtures thereof or extracts containing them.
Les sources d'acide γ-linolénique peuvent être choisies parmi les huiles végétales comme par exemple les huiles d'onagre, de bourrache, de pépin de cassis, d'echium et de chanvre, et les extraits de la microalgue spiruline {Spirulina maxima et Spirulina platensis).  The sources of γ-linolenic acid may be chosen from vegetable oils such as, for example, evening primrose, borage, blackcurrant seed, echium and hemp, and extracts of the spirulina microalgae (Spirulina maxima and Spirulina platensis).
Les huiles végétales de noix, noisettes, amandes (Juglans regia), de coriandre et de soja (Glycina max), de colza (Brassica naptus), de chia, de lin, de rosier muscat et les huiles de poisson, par exemple, sont riches en acides gras polyinsaturés de la série ω-3. Les acides gras polyinsaturés ω-3 peuvent également se trouver dans le zooplancton, les crustacés/mollusques et les poissons.  Vegetable oils of nuts, hazelnuts, almonds (Juglans regia), coriander and soy (Glycina max), rapeseed (Brassica naptus), chia, flax, muscat rose and fish oils, for example, are rich in polyunsaturated fatty acids of the ω-3 series. Polyunsaturated fatty acids ω-3 can also be found in zooplankton, crustaceans / molluscs and fish.
Les huiles de poissons constituent la principale source industrielle d'EPA et de Fish oils are the main industrial source of EPA and
DHA. DHA.
Les biomasses de micro algues peuvent aussi constituer une matière première d'extraction des acides gras insaturés ω-3. Microalgae biomass can also be a raw material extraction of ins-3 unsaturated fatty acids.
Ainsi, un acide gras poly-insaturé peut être mis en œuvre dans une composition de l'invention sous forme d'au moins une huile choisie parmi les huiles d'onagre, de bourrache, de pépins de cassis, de noix, de soja, de poissons, de tournesol, de germes de blé, de chanvre, de fénugrec, de rosier muscat, d'échium, d'argan, de baobab, de son de riz, de sésame, d'amande, de noix, de noisette, de chia, de lin, de rosier muscat, d'olive, d'avocat, de carthame, de coriandre et/ou d'extrait de biomasse microalgues (par exemple spiruline), ou d'extraits de zooplancton. Selon un mode de réalisation, une composition de l'invention peut comprendre des actifs additionnels hydrophiles. A titre d'actifs hydrophiles, on peut utiliser les protéines ou les hydrolysats de protéine, les acides aminés, les polyols notamment en C2 à C10 comme les glycérine, le sorbitol, le butylène glycol et le polyéthylène glycol, l'urée, l'allantoïne, les sucres et les dérivés de sucre, les vitamines hydrosolubles, l'amidon, des extraits bactériens ou végétaux comme ceux d'Aloe Vera. Thus, a polyunsaturated fatty acid can be used in a composition of the invention in the form of at least one oil chosen from evening primrose, borage, blackcurrant seed, walnut, soya, fish, sunflower, sprouts of wheat, hemp, fenugreek, musk rose, echium, argan, baobab, rice bran, sesame, almond, walnut, hazelnut, chia, flax, muscat rose, olive, avocado, safflower, coriander and / or microalgae biomass extract (eg spirulina), or zooplankton extracts. According to one embodiment, a composition of the invention may comprise additional hydrophilic active agents. As hydrophilic active agents, it is possible to use proteins or protein hydrolysates, amino acids, and especially C 2 -C 10 polyols such as glycerol, sorbitol, butylene glycol and polyethylene glycol, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, starch, bacterial or plant extracts such as Aloe Vera.
Selon un autre mode de réalisation, une composition de l'invention peut comprendre en outre un actif lipophile.  According to another embodiment, a composition of the invention may further comprise a lipophilic active agent.
Comme actifs lipophiles, on peut utiliser le rétinol (vitamine A) et ses dérivés, le tocophérol (vitamine E) et ses dérivés, les céramides, les huiles essentielles.  As lipophilic active agents, it is possible to use retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, ceramides, essential oils.
On peut, en outre, associer les actifs selon l'invention à des agents actifs destinés, notamment, à la prévention et/ou au traitement des affections cutanées. In addition, the active agents according to the invention can be combined with active agents intended, in particular, for the prevention and / or treatment of cutaneous affections.
Selon un autre mode de réalisation, on peut aussi utiliser des actifs According to another embodiment, it is also possible to use assets
- qui participent à la cohésion du derme comme la glucosamine, le romarin, la carnitine, la myrtille, la sauge, l'épinard, la fraise, le café vert, la pomme, - who participate in the cohesion of the dermis such as glucosamine, rosemary, carnitine, blueberry, sage, spinach, strawberry, green coffee, apple,
- qui aident au renouvellement cellulaire comme les réinoïdes et les phytohormones, comme la daizèine ou la diosgènine,  - which help cell renewal such as reinoids and phytohormones, such as daizene or diosgenin,
- à valence anti- inflammatoire comme l'hespéridine, la lactoferrine, with an anti-inflammatory valence such as hesperidin, lactoferrin,
- pro-desquamants, - pro-desquamating,
- antioxydants,  - antioxidants,
- anti séborrhéiques,  - anti seborrheic,
- antibactériens, tels que des antibiotiques comme l'érythromycine. Procédé - antibacterials, such as antibiotics such as erythromycin. Process
Selon un autre de ses aspects, la présente invention se rapporte à un procédé de traitement cosmétique par voie orale du teint de la peau, et/ou des désordres cutanés esthétiques associés, qui peut être mis en œuvre notamment en administrant les compositions cosmétiques telles que définies ci-dessus, selon la technique d'utilisation habituelle de ces compositions.  According to another of its aspects, the present invention relates to a method of cosmetic treatment orally of the complexion of the skin, and / or associated aesthetic skin disorders, which can be implemented in particular by administering the cosmetic compositions such as defined above, according to the usual technique of use of these compositions.
Selon un mode de réalisation, l'invention concerne un procédé cosmétique par voie orale utile pour prévenir et/ou traiter les imperfections du teint de la peau chez un individu en ayant besoin comprenant au moins une étape d'administration audit individu d'au moins une quantité efficace d'un acide gras mono-insaturé un de ses sels et/ou un de ses esters, et en particulier de l'acide pétrosélénique.  According to one embodiment, the invention relates to an oral cosmetic method useful for preventing and / or treating imperfections of the complexion of the skin in an individual in need comprising at least one step of administration to said individual of at least one an effective amount of a mono-unsaturated fatty acid, one of its salts and / or one of its esters, and in particular petroselenic acid.
Un procédé selon l'invention peut comprendre une étape consistant à observer une réduction voire une disparition des imperfections du teint de la peau.  A method according to the invention may comprise a step consisting in observing a reduction or even a disappearance of imperfections of the complexion of the skin.
Selon un mode de réalisation, un procédé de l'invention peut de préférence être appliqué à un individu âgé, une femme adulte, un individu présentant une peau de type asiatique ou un individu présentant une peau de type africain.  According to one embodiment, a method of the invention may preferably be applied to an elderly individual, an adult woman, an individual having Asian-type skin or an individual having African-type skin.
Avantageusement, l'application d'un procédé de l'invention peut réduire, voire faire disparaître, les impuretés de la peau, et de préférence de la peau du visage, restaurer un teint homogène, unifié, et/ou dénué d'aspect terne, et favoriser un teint rayonnant.  Advantageously, the application of a method of the invention can reduce or even eliminate impurities from the skin, and preferably from the skin of the face, to restore a uniform, unified complexion and / or lacking a dull appearance. , and promote a radiant complexion.
Un procédé cosmétique selon l'invention peut être mis en œuvre, notamment, par administration d'une composition alimentaire telle que définie ci-dessus.  A cosmetic process according to the invention can be implemented, in particular, by administering a food composition as defined above.
Un procédé de l'invention peut être mis en œuvre de façon journalière par exemple, à raison par exemple d'une administration unique par jour ou d'une administration deux fois par jour, par exemple une fois le matin et une fois le soir.  A method of the invention may be implemented daily for example, for example for a single administration per day or administration twice a day, for example once in the morning and once in the evening.
Un procédé cosmétique selon l'invention peut être mis en œuvre par administration orale, par exemple par administration journalière d'une composition formulée par exemple sous forme de gélules, gels, lotions, dragées, émulsions, comprimés, capsules ou ampoules buvables, en quantité et nombre adéquats, selon leur forme.  A cosmetic process according to the invention can be implemented by oral administration, for example by daily administration of a composition formulated for example in the form of capsules, gels, lotions, dragees, emulsions, tablets, capsules or drinkable ampoules, in quantity. and adequate numbers, depending on their form.
Une quantité efficace d'acide gras mono-insaturé peut être administré en une dose unique par jour ou en doses fractionnées sur la journée, par exemple deux à trois fois par jour. Un procédé selon l'invention peut avantageusement comprendre une administration unique. An effective amount of monounsaturated fatty acid can be administered in a single dose per day or in divided doses over the day, for example two to three times a day. A method according to the invention may advantageously comprise a single administration.
Un procédé cosmétique de l'invention peut être mis en œuvre sur une période de temps variant d'une semaine à plusieurs semaines, voire plusieurs mois, cette période pouvant par ailleurs être répétée après des périodes de non traitement, pendant plusieurs mois voire plusieurs années. A cosmetic process of the invention may be implemented over a period of time varying from one week to several weeks, or even several months, this period being able to be repeated after periods of non-treatment, for several months or even several years. .
A titre d'exemple, l'administration d'un actif selon l'invention peut être répétée, par exemple, 2 à 3 fois par jour, ou plus, et généralement sur une durée prolongée d'au moins 4 semaines, voire 4 à 15 semaines, avec le cas échéant une ou plusieurs périodes d'interruption.  For example, the administration of an active ingredient according to the invention may be repeated, for example, 2 to 3 times a day, or more, and generally over an extended period of at least 4 weeks, or even 4 to 15 weeks, with if necessary one or more periods of interruption.
Un procédé cosmétique orale peut être mis en œuvre sur une période de temps variant d'une semaine à plusieurs semaines, voire plusieurs mois, cette période pouvant par ailleurs être répétée après des périodes de non traitement, pendant plusieurs mois voire p lusieurs années .  An oral cosmetic process can be implemented over a period of time ranging from one week to several weeks, or even several months, this period being able to be repeated after periods of non-treatment, for several months or even years.
A titre d'exemple l'administration par voie orale d'un acide gras mono-insaturé selon l'invention peut être effectuée à raison de, par exemple, 3 fois par jour plus, généralement sur une durée prolongée d'au moins 4 semaines, voire 4 à 15 semaines, comprenant ou non une ou plusieurs périodes d'interruption ou étant répétée après une période d'interruption.  By way of example, the oral administration of a monounsaturated fatty acid according to the invention can be carried out at the rate of, for example, 3 times a day more, generally over an extended period of at least 4 weeks. or 4 to 15 weeks, including or not one or more periods of interruption or being repeated after a period of interruption.
Dans la description et dans les exemples suivants, sauf indication contraire, les pourcentages sont des pourcentages en poids et les plages de valeurs libellées sous la forme « entre ... et ... » incluent les bornes inférieure et supérieure précisées. Les ingrédients sont mélangés, avant leur mise en forme, dans l'ordre et dans des conditions facilement déterminées par l'homme de l'art. In the following description and examples, unless otherwise indicated, percentages are percentages by weight and ranges of values in the form "between ... and ..." include the specified lower and upper bounds. The ingredients are mixed, before they are shaped, in the order and under conditions easily determined by those skilled in the art.
Les exemples ci-après sont présentés à titre illustratif et non limitatif du domaine de l'invention. EXEMPLES The following examples are presented by way of illustration and not limitation of the field of the invention. EXAMPLES
Exemple 1  Example 1
Compositions pour la voie orale  Compositions for the oral route
Exemple 1 A : Stick poudre  Example 1 A: Stick powder
On peut prendre un stick par jour. You can take a stick a day.
La prise quotidienne d'un tel stick pendant environ une semaine permet de conférer à la peau un teint homogène, et lumineux.  The daily intake of such a stick for about a week makes it possible to give the skin a uniform and luminous complexion.
Exemple 1B : Stick poudre Example 1B: Stick powder
On peut prendre un stick par jour. You can take a stick a day.
La prise quotidienne d'un tel stick pendant environ une semaine permet de réduire signifïcativement les dyschromies et de conférer à la peau un teint homogène, lumineux et éclatant. Exemple 1C : Capsule The daily intake of such a stick for about a week significantly reduces dyschromias and give the skin a uniform, bright and radiant complexion. Example 1C: Capsule
On peut prendre une à trois de ces capsules par jour. One to three of these capsules can be taken daily.
La prise quotidienne d'une telle capsule pendant environ une semaine permet de réduire signifïcativement les dyschromies, les rougeurs, et les imperfections cutanées et de conférer à la peau un teint homogène, lumineux et éclatant.  The daily intake of such a capsule for about a week significantly reduces dyschromias, redness, and skin imperfections and give the skin a uniform, bright and radiant complexion.
Exemple 1D : Formulation de type dragée Example 1D: Formulation of the dragée type
Ce type de dragée peut être pris 1 à 3 fois par jour. This type of dragee can be taken 1 to 3 times a day.
La prise quotidienne d'une telle dragée pendant environ une semaine permet de réduire signifïcativement les dyschromies, les imperfections cutanées et de conférer à la peau un teint homogène, lumineux et éclatant. Exemple 1E : Formulation de type dragée Daily intake of such a dragee for about a week significantly reduces dyschromias, skin imperfections and give the skin a uniform, bright and radiant complexion. Example 1E: Formulation of the dragée type
Ce type de dragée peut être pris 1 à 3 fois par jour. This type of dragee can be taken 1 to 3 times a day.
La prise quotidienne d'une telle dragée pendant environ une semaine permet de réduire signifïcativement les dyschromies et de conférer à la peau un teint homogène, lumineux et éclatant.  The daily intake of such a dragee for about a week can significantly reduce the dyschromias and give the skin a homogeneous complexion, bright and radiant.

Claims

REVENDICATIONS
1. Utilisation cosmétique orale ou nutraceutique d'une quantité efficace d'au moins un acide gras mono-insaturé, d'un de ses sels et/ou d'un de ses esters, à titre d'actif pour traiter et/ou prévenir les imperfections du teint de la peau, lesdites imperfections n'étant pas une altération résultant de phénomènes inflammatoires, n'étant pas liées à une surproduction de mélanine, n'étant pas un défaut de surface de la peau ou n'étant pas un défaut de clarté du teint de la peau. 1. Oral or nutraceutical cosmetic use of an effective amount of at least one monounsaturated fatty acid, a salt thereof and / or an ester thereof, as an active ingredient for treating and / or preventing imperfections of the complexion of the skin, said imperfections not being an alteration resulting from inflammatory phenomena, not being related to an overproduction of melanin, not being a surface defect of the skin or not being a defect clarity of the complexion of the skin.
2. Utilisation selon la revendication précédente, pour prévenir et/ou traiter les peaux brouillées, les peaux ternes, les peaux à teint inhomogène, ou les peaux présentant des impuretés ou les dyschromies, et/ou pour permettre de révéler l'éclat du teint. 2. Use according to the preceding claim, for preventing and / or treating blurred skin, dull skins, hides with an inhomogeneous complexion, or skins presenting impurities or dyschromias, and / or to make it possible to reveal the radiance of the complexion. .
3. Utilisation selon la revendication 1 ou 2, dans laquelle la peau est la peau du visage, du cou et/ou du décolleté, et de préférence est la peau du visage. 3. Use according to claim 1 or 2, wherein the skin is the skin of the face, neck and / or décolleté, and preferably is the skin of the face.
4. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle ledit acide gras mono-insaturé, son sel et/ou son ester est utilisé sous une forme isolée ou dans un extrait végétal.  Use according to any one of the preceding claims, wherein said monounsaturated fatty acid, its salt and / or its ester is used in isolated form or in a plant extract.
5. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle l'acide gras mono-insaturé, son sel et/ou son ester, est mis en œuvre dans une composition par voie orale, et dans laquelle la teneur dudit acide gras mono- insaturé, son sel, et/ou son ester, est telle que la dose journalière varie de 0,5 à 2500 mg/jour, et notamment de 5 à 500 mg/j.  5. Use according to any one of the preceding claims, wherein the mono-unsaturated fatty acid, its salt and / or its ester, is implemented in an oral composition, and wherein the content of said mono fatty acid. unsaturated, its salt and / or its ester, is such that the daily dose varies from 0.5 to 2500 mg / day, and in particular from 5 to 500 mg / day.
6. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle ledit acide gras mono-insaturé est l'acide pétrosélinique.  The use according to any one of the preceding claims, wherein said mono-unsaturated fatty acid is petroselinic acid.
7. Utilisation selon la revendication précédente, dans laquelle ledit acide pétrosélinique est utilisé sous forme d'huile d'une ombellifère ou de Gernium sanguneum.  7. Use according to the preceding claim, wherein said petroselinic acid is used in the form of oil of an umbellifer or Gernium sanguneum.
8. Utilisation selon la revendication précédente, dans laquelle ladite huile d'ombellifère est choisie parmi les huiles de graines de coriandre, de cerfeuil, de carotte, de céleri, de cumin, de carvi, de persil, d'aneth, et leurs mélanges.  8. Use according to the preceding claim, wherein said umbelliferous oil is selected from coriander seeds, chervil, carrot, celery, caraway, caraway, parsley, dill, and mixtures thereof .
9. Utilisation selon l'une quelconque des revendications précédentes, dans ledit gras mono-insaturé est utilisé en association avec au moins un actif cosmétique additionnel, en particulier choisi parmi les vitamines B3, B5, B6, B8, C, E, ou PP, les caroténoïdes, les curcuminoïdes, la niacine, les flavonoïdes, un ou plusieurs cation(s) minéral(aux) divalent(s), des bactéries, des extraits bactériens issus de bactéries filamenteuses non photosynthétiques et non fructifiantes, des microorganismes probiotiques, en particulier à acide lactique, des nutriments prébiotiques, ou un mélange de microorganismes probiotiques et/ou un mélange de nutriments prébiotiques. 9. Use according to any one of the preceding claims, in said monounsaturated fat is used in combination with at least one additional cosmetic active, in particular selected from vitamins B3, B5, B6, B8, C, E, or PP. , carotenoids, curcuminoids, niacin, flavonoids, one or more divalent mineral cation (s), bacteria, bacterial extracts from non-photosynthetic and non-fruiting filamentous bacteria, probiotic microorganisms, in particular lactic acid, prebiotic nutrients, or a mixture of probiotic microorganisms and / or a mixture of prebiotic nutrients.
10. Utilisation selon la revendication précédente, dans laquelle ledit microorganisme probiotique est choisi parmi des microorganismes du genre Lactobacillus sp. et/ou Bifidobacterium sp., l'une de leurs fractions et/ou l'un de leurs métabolites.  10. Use according to the preceding claim, wherein said probiotic microorganism is selected from microorganisms of the genus Lactobacillus sp. and / or Bifidobacterium sp., one of their fractions and / or one of their metabolites.
11. Procédé de traitement cosmétique par voie orale, pour traiter et/ou prévenir les imperfections du teint de la peau chez un individu en ayant besoin, comprenant au moins une étape d'administration audit individu d'une quantité efficace d'au moins un acide gras mono-insaturé, un de ses sels et/ou un de ses esters, lesdites imperfections n'étant pas une altération résultant de phénomènes inflammatoires, n'étant pas liées à une surproduction de mélanine, n'étant pas un défaut de surface de la peau ou n'étant pas un défaut de clarté du teint de la peau.  11. A method of oral cosmetic treatment, for treating and / or preventing imperfections of the complexion of the skin in an individual in need, comprising at least one step of administering to said individual an effective amount of at least one mono-unsaturated fatty acid, one of its salts and / or one of its esters, said imperfections not being an alteration resulting from inflammatory phenomena, not being related to overproduction of melanin, not being a surface defect of the skin or not being a defect of clarity of the complexion of the skin.
EP11797362.8A 2010-11-05 2011-11-03 Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections Ceased EP2635140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1059144A FR2967070B1 (en) 2010-11-05 2010-11-05 MONOINSATURE FATTY ACID FOR PREVENTING AND / OR TREATING SKIN DUST IMPERFECTIONS
US34490910P 2010-11-15 2010-11-15
PCT/IB2011/054895 WO2012059880A1 (en) 2010-11-05 2011-11-03 Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections

Publications (1)

Publication Number Publication Date
EP2635140A1 true EP2635140A1 (en) 2013-09-11

Family

ID=43989810

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11797362.8A Ceased EP2635140A1 (en) 2010-11-05 2011-11-03 Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections

Country Status (10)

Country Link
US (1) US9730905B2 (en)
EP (1) EP2635140A1 (en)
CN (1) CN103747692A (en)
BR (1) BR112013011064A2 (en)
CA (1) CA2816732C (en)
CL (1) CL2013001232A1 (en)
FR (1) FR2967070B1 (en)
MX (1) MX353580B (en)
RU (1) RU2013120495A (en)
WO (1) WO2012059880A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2982150B1 (en) 2011-11-09 2016-05-20 Oreal MONO-UNSATURATED FATTY ACID FOR NAIL CARE
FR3005411B1 (en) 2013-05-07 2016-09-30 Laboratoires Inneov ASSOCIATION OF ACTIVE INGREDIENTS FOR ORAL ADMINISTRATION TO ENHANCE THE QUALITY OF NAILS.
FR3005410A1 (en) * 2013-05-07 2014-11-14 Inneov Lab PETROSELINIC ACID AND ZINC ASSOCIATION FOR ORAL ADMINISTRATION TO COMBAT HAIR AGING
JP6204174B2 (en) * 2013-12-10 2017-09-27 日清ペットフード株式会社 Pet food
WO2015121455A1 (en) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprising at least one probiotic
US20170304376A1 (en) * 2015-01-14 2017-10-26 Infant Bacterial Therapeutics Ab Method of activating lactic acid bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725370B1 (en) * 1994-10-07 1997-06-06 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING OIL RICH IN PETROSELINIC ACID
USRE38141E1 (en) * 1997-10-17 2003-06-10 International Flora Technologies Ltd. Dry emollient compositions
WO1999047110A1 (en) * 1998-03-16 1999-09-23 Unilever Plc Cosmetic method of treating skin
EP1013178B2 (en) 1998-12-22 2009-09-16 Unilever N.V. Cosmetic use of petroselinic acid
GB9918022D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
WO2001013956A2 (en) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
WO2008078050A2 (en) * 2006-12-14 2008-07-03 L'oreal Use of at least one mono-unsaturated fatty acid for the treatment of fragile skin, mucous or semi-mucous tissues and scalp
EP1932509A1 (en) * 2006-12-14 2008-06-18 L'oreal Oral use of at least one monounsaturated fatty acid for the purpose of improving hair

Also Published As

Publication number Publication date
CA2816732A1 (en) 2012-05-10
BR112013011064A2 (en) 2016-07-19
RU2013120495A (en) 2014-12-10
US9730905B2 (en) 2017-08-15
US20130302297A1 (en) 2013-11-14
MX353580B (en) 2018-01-19
FR2967070B1 (en) 2013-07-05
CA2816732C (en) 2020-02-18
MX2013005025A (en) 2013-06-03
WO2012059880A1 (en) 2012-05-10
CL2013001232A1 (en) 2013-12-20
CN103747692A (en) 2014-04-23
FR2967070A1 (en) 2012-05-11

Similar Documents

Publication Publication Date Title
CA2510308C (en) Process and compounds for preventing and/or treating sensitive and/or dry skin
EP2332520A1 (en) Probiotic microorganisms as an active ingredient for enhancing skin radiance
FR2938437A1 (en) COSMETIC USE OF MICROORGANISM FOR THE TREATMENT OF OIL SKIN
WO2007015027A1 (en) Cosmetic and/or dermatological composition for prevention and/or treatment of sensitive or dry skin
CA2816732C (en) Use of petroselenic acid to allow the brightness of the skin to be revealed
US9642786B2 (en) Use of a combination of at least one polyunsaturated fatty acid and at least one carotenoid, for improving the quality of the nails
WO2015087277A1 (en) Composition based on a polyunsatured fatty acid and on a carotenoid, for oral administration, for improving hair quality
EP2776012B1 (en) Monounsaturated fatty acid for nailcare
EP1932510B1 (en) Use of petroselinic acid for the treatment of fragile scalps
CA2922480C (en) Orally administered composition based on polyunsaturated fatty acid and vitamin d for improving hair quality
WO2008078050A2 (en) Use of at least one mono-unsaturated fatty acid for the treatment of fragile skin, mucous or semi-mucous tissues and scalp
FR2996128A1 (en) USE OF AN ASSOCIATION OF TAURINE OR ONE OF ITS DERIVATIVES, AND GRAPE EXTRACT FOR IMPROVING THE QUALITY OF NAILS.
FR2943248A1 (en) Cosmetic use of extract of wolfberry as agent for preventing and/or treating scalp disorders, preferably dandruff condition of scalp

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130503

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140710

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160102